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"So once you do know what the question actually is,  
you’ ll know what the answer means.”  
 















recent  years.  Initially  exclusively  discussed  as  being  toxic  waste  products  of  haem 
catabolism, bile pigments are  increasingly considered as being beneficial  in  terms of 
health  promotion  and  disease  prevention.  Data  from  in  vivo  studies  suggest 
vasoprotective,  anti‐inflammatory,  anti‐viral  and  anti‐cancer  properties,  and  in  vitro 
research  attests  anti‐genotoxic  and  anti‐apoptotic  activity  to  these  compounds. 
Despite  such promising  reports, underlying mechanisms of  action  remain essentially 
unknown and are a matter or current research. Especially the prevention of worldwide 
increasingly  chronic  disorders  such  as  cardiovascular  disease  and  cancer  is  of  great 
medical and economic importance, and thus fundamental in vitro research in this field 
is importantly required. Especially testing endogenous compounds such as bilirubin in 
that  regard  and  estimating  the  pigments’  underlying mechanisms  of  action  in  vitro, 
represent meaningful  approaches  towards  deflecting  potential  physiological  effects. 
Therefore, the aim of this study was 1) to enlarge the existing body of evidence on in 
vitro  anti‐mutagenic,  antioxidant  and  anti‐genotoxic  properties with  data  on  newly 
tested  tetrapyrroles,  and  2)  to  explore  possible  underlying mechanisms  of  action  in 
vitro.  The  study  was  performed  within  the  framework  of  the  FWF  project  “The 
physiological relevance of bile pigments” (grant number P21162‐B11), and focused on 
in vitro cell‐ and bacterial culture models.  
In summary,  the majority of  the  tested bile pigments  (especially protoporphyrin and 
the bilirubinoids) acted  in an anti‐genotoxic manner against  synthetic  (2,4,7‐trinitro‐
9H‐fluoren‐9‐one),  food‐borne  (aflatoxin  B1  and  2‐amino‐1‐methyl‐6‐
phenylimidazo[4,5‐b]pyridine)  and  pro‐oxidant  (tertiary‐butyl  hydroperoxide) 
mutagens  in  the Salmonella reverse mutation assay. The obtained results specifically 




and  food‐borne  mutagens.  Especially  bilirubin,  biliverdin  and  bilirubin  ditaurate 
showed  moderate  to  high  anti‐oxidant  properties  in  the  performed  antioxidant 
capacity assays versus  trolox and  iron, and  for  the  first  time  in vitro TEAC and ORAC 
antioxidant  capacities  were  reported  for  urobilin,  stercobilin  and  protoporphyrin. 
Especially these intestinally abundant compounds also induced DNA‐damage in cancer 
cells,  detected  using  the  comet  assay,  which  implies  a  toxic  effect  in  the  applied 
malignant  cell  lines HepG2  and  Caco2.  In  summary,  this  outcome  strongly  supports 
existing  data  on  anti‐mutagenic/anti‐oxidative  activity  and  adds  entirely  novel 
evidence to known in vitro effects of bile pigments and derivatives.  
Although  results  from  in  vitro  studies  cannot  be  directly  transferred  to  the 
physiological condition, an antioxidant/anti‐genotoxic behavior of tetrapyrroles could 
have  implications  for  pathogenetic  processes  associated with  prerequisite  oxidative 
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of  haem  takes  place  1,5.  In  specific,  mostly  unconjugated  bilirubin  (BR;  without 
glucuronates) circulates in the plasma, the majority of which tightly bound to albumin6, 
and  is excreted by  the  liver  1,  to eventually enter  the  intestine.  In  the human body, 
biliverdin  (BV)  is  rapidly  metabolized  to  BR  7.  Thus  BV  cannot  be  measured 







to  the  porphyrin  group  of molecules  10, which  represent  tetrapyrrolic,  dicarboxylic 
acids  carrying extended double‐bond  and π‐electron  systems. Due  to  their  common 
basic structure, this group of molecules  is summarized as “tetrapyrroles” (TPs). Based 
upon their structural properties, either direct structural interactions with molecules (e. 
g.  stacking or non‐/covalent complex  formation with potential mutagens)  5,11 and/or 
an  antioxidant  activity  through  the  donation  of  electrons12  or  hydrogen  (H)  atoms, 
have  been  hypothesized  as  underlying  mechanisms  of  anti‐genotoxic  action. 
Furthermore,  free NH‐groups  13 within  the molecules  have  been  discussed  as  being 
crucial  factors determining  the  compounds’  antioxidant  activity. However,  the exact 
roles structural properties and functional groups attached to the  individual molecules 
play  in  terms of  the pigments’ multidimensional activity remain vastly unknown. The 













With  reference  to  its  antioxidant  function,  it  is  evident  that  BR  scavenges  singlet 
oxygen21  and  is  a  potent  reducing  agent  for  peroxides,  in  the  presence  of 
hydroperoxides 22,23. Biliverdin however only carries an extended double‐bond system, 




protein  albumin.  This  binding  is  thought  to  involve  ion‐pairing,  H‐bonding  and  π‐
interactions  between  the  side  chains  of  amino‐acids  and  the  pigment  itself.  This 





It  is  important  to  note  that  the  ratio  of  bilirubin  to  albumin  plays  a  crucial  role  in 
determining  “free”  bilirubin  concentrations,  since  this  concentration  influences  the 
degree to which bilirubin can diffuse into cells 26.  
Despite  its  numerous  polar  groups,  unconjugated  BR  yet  is  practically  insoluble  in 










Bile  pigments  and  derivatives  are  tetrapyrrolic  dicarboxylic  acids  which  share 
porphyrin  structure.  As  discussed  in  the  previous  paragraphs,  the  individual 
compounds carry different functional groups and side‐chains and can be cyclic (fused) 
or  linear  (open‐chain)  in conformation. Figure 1, presents  the chemical  structures of 
the  tested  TPs,  followed  by  specifications  on  the  pigments’  chemistry,  in  the 
chronological  order  of  their  physiological  occurrence.  Physiologically  abundant  TPs 
mainly  include  PRO,  BV,  un‐/conjugated  BR,  SB  and  UB.  The  methyl  esterified 























































Protoporphyrin  IX  is  the  only  naturally  occurring  isomer  of  the  group  of 
protoporphyrins, and represents the direct precursor of haem. Like haem,  it  is red  in 
color  and  contains  four  methyl,  two  propionic  and  two  vinyl  side  chains. 
Protoporphyrin  is  produced  by  oxidation  of  the  methylene  bridge  of 












accompanied by  the  loss of  iron  (Fe3+), and a  carbon atom  in  the  form of CO, after 
NADPH/H+‐dependent  oxidation  at  haem’s  α‐methene  bridge,  involving  the  iso‐






















groups  (e.  g.  the  two  propionic  acid  side  chains  and  amino  groups) make  it  highly 















This  yellow  colored  open‐chain  molecule,  also  referred  to  as  “taurobilirubin”  32, 
represents  the  synthetic  analogue  to  physiologically  abundant  conjugated  (“direct”) 
BR, which  in  the  human  body  is  responsible  for  a  balanced  BR  threshold.  Bilirubin 
glucuronides are natural human metabolites of BR, generated  in  the  liver by uridine 
diphosphate  (UDP‐)  glucuronosyltransferase  1A1  (UGT1A1),  forming  β‐1‐o‐glycosidic 
bonds. Glucuronides  of  BR  are  formed  through  esterification  of  BR’s  propionic  acid 
groups with monosaccharides  (D‐glucose, D‐xylose),  and uronic  acid  33. The  resulting 
molecule  is  highly  water‐soluble  based  on  the  cleavage  of  H‐bonds  between  the 












Orange  coloured  BR‐DME  is  (synthetically)  formed  through  esterification  of  BR  and 
methyl  groups  (methanol).  Involving  esterases  and  UDP‐glucuronosyltransferase, 



















This molecule represents  the  final product of  the  intestinal BR degradation  37.  In  the 
colon, BR is fermented by the microflora. After enzymatic elimination of glucuronates 








g.  structural  interactions/complexation,  anti‐oxidant  action  etc.),  various  mutagens 
















From  centuries  ago until present,  salts of BR have been used  in Traditional Chinese 
Medicine  (TCM)  to  treat  and  cure diseases  and  conditions  associated with  acute  or 
chronic  inflammation  38. Originally, pulverized gallstones  (calculus bovis) of  the Asian 
cattle  breed  “Bos  Taurus  Domesticus  Gmelin”  (fam.  bovidae)  were  used,  whereas 
today mostly  the synthetic  form  is applied,  for normalizing gall bladder  function and 
treating  inflammation  and  fever  39.  Recently,  also  data  on  immune‐modulating  and 
anti‐carcinogenic effects of calculus bovis have been published 40. 
By  the  academic medicine  and  the  scientific  community  however,  BR was  for  long 
considered  useless  at  its  best  or  toxic  at  its  worst  41,  and  elevated  BR  plasma 
concentrations were exclusively  considered  in  connection  to disease.  It  is only  since 
the  late 1990s  that  the  scientific opinion on BR and  related BPs has  shifted. Due  to 
growing  evidence  on  anti‐mutagenic  and  antioxidant  effects  in  vitro  5,42‐46  and  a 
recently evident anti‐atherogenic  in vivo action  in the broadest sense 47‐49, BR and  its 
derivatives  are  now  regarded  as  being  beneficial  in  terms  of  health  promotion. 
Elevating  circulating  BR  levels50  could  represent  a  promising  approach  towards 
preventing  or  curing  inflammatory  diseases  such  as  coronary  heart  disease  25,47,48,51 




Bilirubin  and BV  are produced within  the enzymatic haem  catabolism, which begins 
inside macrophages  of  the  spleen. Hemoglobin  (Hb)  is  released  from  senescent  red 
blood cells, as well as  from non‐erythroid hemoproteins  (e. g. cytochrome  systems), 
representing  the  two major  sources  of  organic  haem  for  the  production  of  BPs  54. 
Haem  to which PRO  represents  the direct precursor,  is degraded  involving  the  rate‐




stress,  HMOX‐1  expression  is  increased, which  should  protect  from  the  deleterious 
effects of free (pro‐oxidant) haem 55. From the oxidative HMOX‐1 reaction, equimolar 
amounts  of  BV,  carbon  monoxide  (CO)  and  trivalent‐iron  (Fe3+)  are  liberated. 
Subsequently, BR  is enzymatically produced  from BV,  involving the reductive enzyme 
NADPH/NADP+  BLVRA, which  is  highly  expressed  in  the  cytosol  of most  eukaryotic 
cells27.  
Due  to BR’s  strong affinity  for albumin  22,28 and  its  limited  solubility  in  the aqueous 
phase, most of  the  formed unconjugated BR  is bound  to albumin  in  the plasma and 
transported to the  liver, where  it  is taken up  into hepatocytes via active and passive 
modes  of  absorption  56.  From  there,  BR  is  shifted  to  the  endoplasmic  reticulum 
involving glutathione‐S‐transferase, where glucuronic acid conjugates (esterification of 
propionic  acid  side‐chains  with  mono‐  and  mainly  diglucuronides)  are  formed  by 
UGT1A1 1,57. The process of conjugation changes  lipophilic BR to water‐soluble BR 56, 
and thereby enables its urinary excretion. Under normal circumstances, the majority of 
plasma BR  is unconjugated 6. This  is  important, since  large amounts of conjugated BR 
in the plasma could bind irreversibly to albumin, generating δ‐BR and thereby forming 
a potentially toxic non‐excretable complex 6.  
Multidrug  resistance  protein  2  (MRP2) ATP‐dependently  transports  BR  into  the  bile 
caniculi 58, and BR conjugates are finally released into the duodenum via the bile duct. 
Upon entry  into the  intestinal tract, unconjugated BR  is formed by bacterial enzymes 
including β‐glucuronidase. Parts of  the product are excreted,  large parts of  it are  re‐
absorbed  via  entero‐hepatic  recirculation  (approx.  70 %)  59,60.  Remaining  pigments 
undergo a series of  reductions  involving  the  intestinal microflora, and  leading  to  the 
formation of UB and SB 61,62. The BR metabolites, urobilinogen (UBG) and urobilinoids 








and  faeces  every  day  24.  As  mentioned,  also  the  direct  haem  precursor  PRO 
accumulates  in  the  intestinal  tract and  is excreted  in  the  faeces at concentrations of 

















Figure 3.  Schematic bile pigment metabolism  –  from haem  to BR. Hemoglobin  is  split  to 
yield  globin  and  hematin,  a  hydroxide  of  the  trivalent‐iron  derivative  of  haem  (not 
illustrated). Haem is enzymatically converted to BV by removing iron, and by oxidation at its 
α‐methene bridge, with  loss of a carbon atom  in  the  form of CO. This opens  the porphyrin 





















































Figure  4.  Schematic  bile  pigment  metabolism  –  from  BR  to  SB  and  UB. Most  of  the 
formed BR  is bound  to plasma  albumin  and  transported  to  the  liver, where  albumin  is 
removed,  and  glucuronidation  occurs,  to  form  conjugated  BR.  Conjugated  BR  can  be 
excreted  via  the  urine.  Some  of  it  however,  enters  the  intestinal  tract where  bacterial 








Jaundice  and  cholestasis  both  result  in  yellow  coloration  of  the  skin,  mucous 
membranes, and sclera, however the conditions should be clearly distinguished  from 
one  another.  Cholestasis  refers  to  a  decreased  flow  rate  of  the  bile  (e.  g.  due  to 
obstruction  of  bile  caniculi), whereas  jaundice  can  have multiple  underlying  causes 
including hepatitis, gallstones, pancreatitis, hemolysis as well as existent genetic non‐
hemolytic conditions of hyperbilirubinaemia 64. Thus, jaundice can either be acquired, 
or  hereditary.  For  an  initial  differential  diagnosis,  different  fractions  of  BR  can  be 
measured. In the clinic, circulating total BR levels are routinely measured, representing 
the  sum  of  both  unconjugated  (indirect)  and  conjugated  (direct)  BR.  Besides, 





Under  physiological  circumstances,  circulating  plasma  BR  concentrations  in  humans 
range between 8.5 and 17 µM 1 (1 – 5 µM conjugated), the major part of which being 
albumin‐bound 65. Inherited chronically elevated circulating total BR levels can result in 
specific  harmless  conditions  or  harmful/severe  diseases  followed  by  a  plethora  of 
symptoms,  since  free,  unconjugated  BR  is  toxic  to  various  cell  types,  in  specific 
neurons6,66,67.  The  crucial  factor  determining  disease  severity  and  (neuro‐)toxicity  is 
the  activity  of  the  iso‐enzyme  UGT1A1,  which  is  based  on  mutations  in  its  gene 
promoter  region.  Depending  on  the  enzyme’s  remaining  activity,  conditions  of 
hyperbilirubinaemia  do  or  do  not  require  treatment.  If  required,  BR‐associated 
disorders  can  be  controlled  by  applying  certain  medications  (e.  g.  phenobarbital), 
phototherapy, and  if necessary can be cured by  liver transplantation 68. The following 
paragraphs  list  the  most  commonly  known  conditions  of  inherited 












subjects  70.  The UGT1A1  gene  carries  a  TA  repeat promoter polymorphism which  is 
located 41 nucleotides upstream of the translational start site adjacent to a putative 
TATA  box  71.  The  polymorphism  includes  five  to  eight  TA  repeats, with  six  repeats 
representing  the  most  common  allele  72.  The  condition  is  more  or  less  free  of 
symptoms and liver morphology in affected subjects is normal. Serum BR levels can be 
elevated  by  fasting  73, which  besides  genetic  analysis  also  represents  an  important 
diagnostic tool. Due to the fact that today moderately elevated BR levels are discussed 










that  mild  condition,  BR  levels  can  be  therapeutically  lowered  by  administering 
phenobarbital,  which  induces  microsomal  enzymes,  including  UGT1A1.  Less  severe 
23 
 




The  autosomal  recessive  mostly  asymptomatic  Dubin  Johnson  syndrome,  is 
characterized by increased un‐/conjugated (total) BR levels (around 5 mg/dl or 86 µM; 
higher  levels possible), based on the  inability of hepatocytes to transport conjugated 
BR  into the bile caniculi, which  is due to a mutation  in the MRP2 gene. The patients’ 






to Dubin  Johnson  syndrome,  not  the  transport  of  BR  into  the  bile  caniculi,  but  the 




This  intrinsically  non‐inherited,  but  acquired  condition,  is  due  to  a  delayed 
development  of UGT1A1  expression  and  activity,  in  addition  to  elevated  hemolysis, 
both  of  which  representing  the  most  important  causes  of  neonatal  unconjugated 
hyperbilirubinaemia6. Plasma BR  levels reach concentrations of up to 11.7 mg/dl (200 
µM)  and  normalize  after  a week  to  settle  at  around  1.17 mg/dl  (20  µM)  78,79.  This 
basically physiological condition during the first days of life can become fatal when BR‐





inherited  forms  of  UGT1A1  deficiencies  are  present  80.  Infants with  high  BR  levels 
receive  phototherapy  in  the  blue‐green  spectrum  (430  –  490  nm),  which  leads  to 




Another  congenital  (autosomal  dominant)  disorder  of  BP metabolism,  however  not 
directly  related  to  BR  but  its metabolism  in  the  broadest  sense,  are  (besides  other 
forms  of  protoporphyria),  hepatic  and  erythropoietic  conditions  of  protoporphyria. 
Both of which  represent genetic disorders of haem biosynthesis, which cause severe 
photosensitivity  against  visible  light  in  the  case of  erythropoietic protoporphyria, or 
mostly abdominal pain  in  the hepatic variant.  In either of  the  two, protoporphyria  is 
due to a deficiency in the enzyme ferrochelatase, responsible for converting PRO into 





recent  data  from  human  trials  strongly  suggest  that  especially  BR  is  of  specific 
physiological  importance  and  biological  relevance  in  terms  of  preventing  certain 
diseases. However,  its  exact mechanistic  properties  in  the  human  organism  remain 
uncertain, and further possible roles derivatives of BR could play in the body are vastly 
unknown. Therefore, during the recent years many groups have dedicated their work 









that BR’s  functions as  important antioxidant  14,48 and anti‐inflammatory agent  49,83  in 
the  human  organism  possibly  form  the  main  prerequisite  for  protection  against 
atherosclerosis.  The  compound  exerts  its  function  by  preventing  the  pathogenetic 
peroxidation of lipoproteins such as low density lipoproteins (LDL)/small dense LDL84,85 
and by protecting against plaque  formation  in the  intima 82,86.  In that regard, several 
studies have reported that subjects with lower BR levels are at higher risk for coronary 
and atherosclerotic diseases  49,86‐88, as well as  for coronary artery calcification  89 and 
stroke  90.  In  this  context  it  has  been  vice  versa  reported  that  elevated  BR  provides 
coronary protection in terms of lowering the atherosclerosis risk 82,91 and the severity 
of existing disorders of  the circulatory  system  92. With  reference  to  that  it has been 






loss  should  be  considered  also  in  connection  to  BR’s  suspected  health  promoting 
effects  52.  These  results  have  lately  been  confirmed  by  lowered  BR  levels  in  obese 
persons  96,97,  and  in  the  opposite,  by  lower BMI  values  in  persons with moderately 
elevated BR levels 75.  
In  summary,  lower BR  levels which are based on various genetic and environmental 
factors (e. g. smoking, eating habits, enzyme expressions), seem to be an evident risk 
factor for atherosclerotic events and associated diseases 27. However, since research in 
this  field  is  fairly  young  and  has  so  far mainly  focused  on  exploring  BR’s  biological 
potential,  in  vivo  properties  of  other  members  of  the  haem  catabolic  pathway  or 
26 
 
interrelation  of  these  and  their  effects  on  cardiovascular  protection  are  currently 
unknown  52.  Also  very  recently,  controversy  arose  concerning  BR’s  direct  systemic 
cardioprotective effects.  In a study by Stender et al., commented by  Johansen et al., 
the statistical approach of Mendelian randomization and multifactorial adjustment for 
BR  concentration  was  used,  to  estimate  whether  or  not  elevated  BR  levels  in 
connection  to  the  underlying  UGT1A1  polymorphism  were  directly  involved  in  the 
prevention  of  ischemic  heart  disease  and  myocardial  infarction.  Based  on  their 
analyses  the  authors  concluded  a  non‐causal  relationship  between  BR  and  the 
occurrence  of  the  aforementioned  diseases,  which  would  imply  that  the  above 
mentioned polymorphism does not directly mediate cardioprotection. Indirect effects 
of elevated BR  levels such as  the prevention of oxidation  (e. g. of blood  lipids) were 







non‐dermatological  and  colon  cancer  99,  breast  cancer  100,  as  well  as  a  lowered 
generalized  cancer  mortality  101  only  to  mention  a  few,  have  been  reported  in 
connection to elevated serum BR levels. In the study of Ching et al., the relative risk for 




decreased  with  increasing  serum  BR  levels  101.  In  a  US  study  by  Zucker  et  al.,  an 
increase  in  serum  BR  was  associated  with  a  reduced  lifetime  prevalence  of 
gastrointestinal  and  colorectal  cancer,  with  odd’s  ratios  of  0.81  and  0.26  53. 





Albeit,  potential  anti‐carcinogenic  properties  of  related  TPs  in  vivo,  with  the  only 
exception  of  PRO,  remain  essentially  unknown  to  date,  and  the  majority  of  the 
published literature exclusively reports on in vitro data (see section 1.3.6.2 and paper 
5).  In  either  case,  the  exact  underlying mechanisms  of  a  possible  anti‐carcinogenic 




cancer effects  is PRO. Due to  its photosensitizing properties,  it  is successfully used  in 
the  clinical  treatment  of  different  forms  of mainly  skin  cancer. After  injection  of  5‐
aminolevulinic acid (ALA),  leading to  increased PRO synthesis 103,104,  light‐excited PRO 
molecules  selectively  target  cancer  cells  via  different  mechanisms,  including 





It  has  been  reported  that  BR  positively  influences  glucose  tolerance  106,  diabetes‐
associated  albuminurea  107,  and  the  occurrence  of  the  metabolic  syndrome  108. 
Furthermore,  inverse  correlations  of  elevated  BR  concentrations  with  multiple 
parameters specifying the general metabolic state (insulin resistance, apolipoprotein B, 
triglycerides,  obesity  and  hypertension)  were  found  and  published  by  Ko  et  al., 
Inoguchi et al., and Papadakis et al.106,109,110.  
Referring to the metabolic state  in diabetes and  its connection to BR, several groups 
have  suggested  a  relation  between  certain  enzymes  of  BP metabolism  and  type  2 
28 
 





has  been  shown  to  be  associated  with  improved  insulin  signaling  and  glucose 
metabolism 119‐121.  
In  contrast,  plasma  HMOX  levels  were  found  to  correlate  with  impaired  glucose 
regulation, in which prerequisite elevated glucose levels as a causative factor possibly 
led  to  elevated  oxidative  stress  111.  Vice  versa,  high  plasma  glucose  was  found  to 
induce HMOX‐1 116, fuelling the circle of elevated oxidative stress, and confirming the 
aforementioned  results.  In  contrast, BLVRA  reportedly  could  represent an  important 
counter‐regulatory factor to impaired glucose metabolism, in that it leads to improved 
insulin  sensitivity  115,  diminishes  insulin  signaling  and  reduces  glucose uptake  113,114. 
These properties of BLVRA could be used in future as a therapeutic approach towards 
reducing  insulin  resistance  and  the  negative  consequences  of  a  pathologic  glucose 






Data  from  the  literature  suggest, BR might  exert  a  plethora  of  additional  beneficial 
effects in the human organism, including anti‐inflammation, direct intracellular effects 
via  cell  signaling  and  antioxidant  function  through  the  scavenging  of  overproduced 
ROS 52. As mentioned in section 1.3.5.1., BR suppresses the oxidation of lipids, proteins 
and  lipoproteins  (mainly  LDL)  14,  its  concentration  in  the  human  body  is  directly 
correlated  to  the  total antioxidant  capacity  (TAC) of human  serum  48, and BR  is  the 





stages  in  the  circulation  which  include  protection  against  lipoprotein  peroxidation, 




confirmed  by  Bulmer  et  al.  25,  multiple  potential  candidate  events  come  into 




and  UGT1A1,  enzyme  expression  could  have  important  impact  on  the  disorders 
discussed  in  the previous paragraphs. For example HMOX‐1 has been proposed as a 
more  promising  target  for  treating  oxidative‐stress‐mediated  diseases,  rather  than 
provoking  a  systemic  increase  in  antioxidants  through  supplementation  16.  In 
summary, these results emphasize BR’s antioxidant ability to  lower the prevalence of 
oxidative stress‐mediated disorders 47,52 such as neurodegenerative diseases 124. Anti‐
inflammatory properties have been suggested  in  that  respect  (e. g.  in demyelinating 
neuropathies  such  as multiple  sclerosis)125.  Besides,  also  rare  reports  on  a  possible 
anti‐viral activity of BR via different hypothesized mechanisms exist 126,127.  
Although BR’s possible physiological  importance was already  reported  in 1954  128,  it 
was only  in the year 2007 that  its clinical efficacy 129 and potential clinical application 
were proposed. There exists evidence from an animal trial, according to which BR and 
BV  possibly  prevent  clinical  complications  such  as  sepsis  and  post‐traumatic  stress 
after  surgery  130, however  further  information  is  still  limited. Based on  such  reports 
and  on  BR’s  evident  beneficial  in  vivo  properties,  discussions  about  enteral 












majority  of  the  published  data  however  exclusively  deals  with  anti‐mutagenic  and 
antioxidant effects of BPs and derivatives against multiple classes of mutagens  in the 
Salmonella  reverse  mutation  assay  5,11,42,134‐136,  and  more  rarely  in  cell  culture 
studies137‐139.  Besides,  also  antioxidant  effects  have  been  discussed  within  the 
literature 5,140. So far, mainly the core compounds un‐/conjugated BR and BV as well as 
their more distantly related derivatives hemin, chlorophyll and chlorophyllin have been 
explored42,134,135,137.  Specifications  on  the  pigments’  anti‐mutagenic  and  antioxidant 
effects are presented and discussed in papers 1, 2, 3 and 4.  
Antioxidant  activities  of  BR  in  vitro  other  than  those  detected  by  using  Salmonella, 
have  been  investigated  utilizing  physic‐chemical  methods  and  antioxidant  capacity 
assays,  which  have  also  been  applied  in  the  present  study  (paper  2).  Numerous 
publications45,140,141, have reported that each molecule of BR was able to scavenge 1.9 
molecules  of  peroxyl  radicals,  and  that  BV  was  comparatively  more  efficient  by 
scavenging 4.7 molecules. Furthermore it was proposed that both BPs acted in synergy 
with membrane‐bound α‐tocopherol 24, and that they were able to scavenge one‐ and 
two‐electron  oxidants  including  singlet  oxygen,  peroxyl  radicals  and  α‐tocopheryl 
radicals 142, just to mention a few. Bilirubin was found to more effectively protect lipids 
from oxidation  than water‐soluble glutathione  14,  and was  thirty  times more potent 
against  LDL  oxidation,  compared  to  trolox  85.  Albumin‐bound  BR  at  physiological 










role  in  defending  against  cancer  by  interfering  with  pro‐carcinogenic  signaling 
pathways, and therefore potently inhibits tumor cell proliferation 143. Furthermore, BR 
has been shown to  induce mitochondrial depolarization  in colon cancer cells,  leading 
to  apoptosis  in human  gastric  cancer  cells  and  to  arrest  cell  cycle  144.  Furthermore, 
some  reports  on  anti‐carcinogenic  effects  of mainly  BR  and  PRO with  and without 
prerequisite  photodynamic  excitation  in  cultured  cells  exist  41,143‐147.  However, 
mechanistic  specifications  on  the  behavior  of  other  BR  metabolites  on  cancer  cell 
biology are entirely lacking, with the exception of one report on UB, published by Rao 
et  al.  41.  Despite  the  clinical  use  of  PRO  and  its  derivatives  in  the  photodynamic 
treatment  of mainly  skin  cancer  147,148,  in  vitro  (comet)  data  and  evidence  on  pro‐

















 To  explore  underlying  mechanisms  of  anti‐genotoxic  action  by  testing 
structural  interactions  of  BPs  and  mutagens,  by  using  the  techniques  of 
(vibrational) circular dichroism. 
 To  investigate bacterial test compound absorption and  its relationship with 
anti‐genotoxic pigment properties. 
 To  assess  possible  anti‐genotoxic/anti‐carcinogenic  TP  effects  by  applying 
the  single  cell  gel  electrophoresis  (SCGE/comet)  assay,  and  thereby 
measuring DNA‐damaging effects in human cancer cell lines. 
 To  test  the pigments’ potential  to  induce apoptosis and necrosis, uncouple 












All  chemicals were purchased  from  Sigma Aldrich, Austria  (unless otherwise noted), 









Certain  mutants  of  Salmonella  typhimurium  (S.  typhimurium)  are  not  capable  of 
synthesizing the amino acid histidine. After adding a mutagenic substance, the bacteria 
revert  to  their  wild  type,  which  forms  the  technical  basis  for  the  assay.  When 
Salmonella  tester  strains are grown on minimal glucose agar plates  containing  trace 
amounts of histidine, only those bacteria that revert to histidine‐independence (his+), 
are  able  to  form  colonies  152.  To  classify  a  substance  as  genotoxic,  the  number  of 
revertant colonies on  the plates carrying  the  test compounds must exceed  twice  the 
number of colonies produced on the solvent control plates (negative control) 152.  
In  this  study,  Salmonella  strains  TA98  and  TA102  were  used  to  consider  different 
mechanisms of mutations. The DNA repair proficient strain TA102 detects cross‐linking 
agents and can be reverted by mutagens which cause oxidative damage. Strain TA98 






Maron and Ames  153, and  included a pre‐incubation period of 25 min at 37  °C. This 
technique  allows  closer  contact  between  bacteria,  test  compounds  and  positive 
controls. Some genotoxic and carcinogenic chemicals  (e. g. poly‐/heterocyclic amines 
such as AfB1 and PhIP), are biologically  inactive unless  they are metabolized  to  their 
active  forms,  or  vice  versa,  mutagens  are  active  but  are  inactivated  whilst  being 
metabolized.  Since  bacteria  do  not  possess  a  cytochrome‐based  P450  metabolic 
oxidation system, a rodent activation system was applied, which consisted of a 9000 x 
g  supernatant  fraction  of  a  liver  homogenate  from  Aroclor  1254‐treated  rats  (S‐9 
microsomal fraction; S9‐mix), and was delivered to the test system in the presence of 
NADP and cofactors for NADPH‐supported oxidation. The S9‐mix consisted of 19.75 ml 
of  dH2O, 25 ml 1 x PBS buffer, 0.5 ml MgCl2  (0.85 M), 0.5 ml KCl  (1.65 M) and 2 ml 
































































The  experiments  were  performed  in  a  dimly  lit  laboratory  under  sterile  working 
conditions. 200 µl of BP solution (prepared  in DMSO), 100 µl of mutagen solution (in 












Prior  to  the  tests  being  conducted,  respective  solubilities  of  BPs  and  related  test 
compounds were analyzed. Based on preceding experiments of Bulmer et al. 5 and a 
series  of  solubility  experiments  which  included  supernatant  analysis  conducted 
photometrically at 380 (verdinic compounds) and 450 nm (rubinoid compounds), and 
HPLC analyses after high‐speed centrifugation,  the  following TP concentrations were 








For  the  antioxidant  capacity  assays  TEAC,  FRAP  and ORAC,  TP  stock  solutions were 
prepared in DMSO at concentrations of 2.5, 0.75, and 0.25 mM for BV and BRDT, and 
at 0.75, 0.5 and 0.25 mM for the remaining compounds, due to solubility  limitations. 











and were  lysed  for  30 min  in  40  µl  of  isocratic mobile  phase  (950 ml  HPLC  grade 
methanol, 50 ml HPLC grade water, 24.2 g n‐diocylamine and 6.01 g glacial acetic acid 
per litre mobile phase). Supernatants were diluted therein at 1:4, and run on a Hitachi 
ELITE  LaChrom  HPLC,  equipped  with  a  Shimadzu  SPD‐M20A  detector,  over  a  C18 
reverse phase column (5 micron, 250 x 4.6 mm) and an injection volume of 50 µl 154,155. 








7‐aminoactinomycin‐d  (7‐AAD)  for  guanine‐cytosine  DNA‐base  pairs.  In  viable  cells 
phosphatidyl  serine  is  localized  on  the  inside  of  the  cell,  and  opts  out  during  the 
process of apoptosis. 1 x 106  cells/ml were washed  in Ca2+/Mg2+‐free 1 x phosphate 
buffered  saline  (PBS; PAA Austria)  and  re‐suspended  in binding buffer, were doubly 
labeled with PE‐stained annexinV (exmax: 496, emmax: 575 nm; FL‐2), and 7‐AAD (exmax: 
546,  emmax:  647  nm;  FL‐3)  and  were  incubated  for  15  min  in  the  dark  prior  to 
measurements.  Intact  cells  react negative  to both agents; early apoptotic  cells  react 
positive to annexinV, however negative to 7‐AAD. In late apoptosis and necrosis, cells 




Apoptosis and necrosis  represent  two different  types of cell death. Apoptosis – also 
referred to as programmed cell death – states a genetically determined, physiological 
“suicidal” program which differs significantly from necrosis 157. Apoptosis which can be 
triggered  in‐  or  extrinsically,  is  a  highly  selective  non‐inflammatory  process  158, 
characterized by nuclear condensation, decrease of mitochondrial membrane potential 
through  the  release  of  cytochrome  c,  caspase  activation,  cell  shrinkage  and 
fragmentation  as  well  as  by  the  final  generation  of  apoptotic  bodies.  In  living 
organisms, elevated as well as decreased apoptosis rates may result  in malignancies, 
and  maintaining  the  equilibrium  between  cell  proliferation  and  cell  death  plays  a 
crucial  role  in  cell  physiology.  Therefore,  tissue  homeostasis  is  dependent  on  the 
balance  between  cell  proliferation  and  cell  death  159.  An  imbalance  can  result  in 
diseases  connected  to undesired apoptosis or  cell growth.  In healthy  cells apoptosis 
has  been  linked  to  the  activation  of  the  tumor  suppressor  protein  p53,  whose 
expression in most tumors is down‐regulated 159. 
In  contrast  to  apoptosis,  necrosis  is  basically  the  passive  “accidental”  result  of 























impair  cellular  regulatory  processes  (e.  g.  respiratory  chain‐uncoupling  in 
mitochondria) and  lead  to  cell damage and apoptosis  through  the  state of oxidative 
stress. To detect  intracellular superoxides and (hydro‐)peroxides  in HepG2 and Caco2 
cells,  10  µM  final  concentration  of  dihydroethidium  (DHE)  and  25  µM  final 
concentration of dihydrofluorescein diacetate  (DCFH‐DA), both  in DMSO, were used. 
DHE  is  cell‐permeable  and  specifically  reacts  with  O2‐  to  form  oxyethidium.  This 
product  interacts  with  nucleic  acids  and  emits  red  fluorescence,  which  can  be 
measured cytometrically (exmax: 329, emmax: 373 nm; FL‐2) 160. When DCFH‐DA enters 
the  cell,  it  is  cleaved  by  intracellular  esterases  to  form  dihydrofluorescein  (DCFH), 























11. Stain cells with 10 µM  (final concentration) of DHE  in 1 x PBS and  leave  to 
incubate for 20 min 










4. Add DCFH at a final concentration of 25 µM per well and  leave to  incubate 
(37 °C, dark) for 15 min 
















cycle  (G0/1,  S,  G2/M),  as  well  as  apoptotic  cells  (sub  G0/1),  according  to  the 
fluorescence  intensity  which  is  based  on  the  number  of  DNA  copies  in  the  cell. 





















apart  cell  membranes  and  denatures  proteins  –  suspensions  become 
cloudy) 
7. Centrifuge tubes at 2500 rpm (267 rcf) for 5 min 




11. Discard  supernatants and  stain DNA with 50 µl of 100 µg/ml RNase  (in 
dH2O) per tube 
12. Add 200 µl of 50 µg/ml PI solution (in dH2O) to each tube 




Antioxidants play a  crucial  role  in preventing  free  radical  formation and  their action 
within  the  serum  as  well  as  in  the  cellular  milieu.  To  assess  the  antioxidant  and 
reducing power of structurally related TPs, the trolox equivalent antioxidant capacity 
test  (TEAC),  oxygen  radical  absorbance  capacity  assay  (ORAC)  and  ferric  reducing 






The  TEAC  assay  is  a  cupric  ion  reducing  antioxidant  capacity  spectrophotometric 
method, which measures  antioxidants  at  physiological  pH.  Trolox,  a  cell‐permeable, 




assay  measures  hydrophilic,  lipophilic  and  total  antioxidant  capacity  based  on  the 










is  triggered  by  thermal  decomposition  of  azo‐compounds  (2,2’‐azobis(2‐amidino‐
propane)  dihydrochloride,  AAPH).  It  measures  lipophilic,  hydrophilic  and  total 
antioxidant capacities of substances. Over  time,  radicals generated  from  the  thermal 
decomposition of AAPH are able to quench the  fluorescent probe signal. Subsequent 














In  the  FRAP  assay,  reduction  of  the  ferric  tripyridyltriazine  complex  (Fe3+)  to  the 
ferrous  complex  (Fe2+)  is measured  at  593  nm,  at  low  pH. Change  in  absorbance  is 




2.5  ml  of  20  mM  Fe‐III‐hexahydrate)  and  was  kept  at  37  °C  throughout  the 
experiments. The change  in absorbance was measured at 540 nm every 36 s over six 





As  a  reference  parameter  for  bacterial  protein  content,  the  total  protein  in  each 
sample  (bacterial  colonies) was measured photometrically  167,  in which albumin was 
used as an external standard. Lysed sample supernatants  (centrifuged at 14.000 rpm 
(1.493  rcf)  for  five minutes) were  diluted  at  1:30  in  Bradford  reagent  in  disposable 
semi‐micro cuvettes and read on a Perkin Elmer Lambda 2 UV/VIS spectrophotometer 
at 595 nm, after 17 min of dark incubation. Bacterial TP absorption was calculated and 
















fixed  on  agarose  pre‐coated  microscope  slides  (1  %  low  melting  agarose,  LMA; 
Invitrogen  Austria).  After  lysis  at  pH  ten  and  20 min  of DNA  unwinding,  as well  as 
subsequent 300 µM tert‐BOOH treatment for positive controls, cells were exposed to a 
directed electric field (Electrophoresis CSL‐10M40, Biozym Austria; 25 V, pH >13). After 
EtBr  staining  (20  µl  of  20  µg/ml  per  gel),  DNA  migration  was  assessed  using  a 
fluorescent microscope (Zeiss Germany) equipped with a camera (Hitachi Austria) and 
the software Komet 5.5.  (Andor Technology, Germany). Comet  tail DNA content was 
quantified and expressed as percentages  (%  tail DNA). The applied method  followed 
the protocols of Singh et al. 171, modified by Azqueta et al. 169, to measure both DNA 







It  is well  established  that  under  certain  conditions  BR  and  BV  adopt  chiral  “ridge‐
tile”172‐175 and helical “lock‐washer” 176 conformations, both of which are stabilized by 






upon  complexation  with  the  chiral  host  177,178,  and  become  optically  active.  This 
enables  to  follow  the  subtle  structural  changes  using  circular  dichroism  (CD) 
spectroscopy 176,179. The method refers to the differential absorption (attenuation) of 
left  and  right  circularly  polarized  light.  The  vibrational  variant  of  circular  dichroism, 
vibrational circular dichroism  (VCD),  is a CD  technique applied  in vibrational  spectra, 
and  extends  CD  spectra  into  the  infrared  and  near‐infrared  ranges.  It  follows  the 
vibrational transitions that are localized in a molecule and can therefore determine the 




was  obtained  as  an  average  of  three  accumulations.  Spectra  were  corrected  for 
baseline by subtracting  the spectra of  the corresponding solvents. Circular dichroism 




chiral discriminator  for BR and BV at a pigment/HSA molar  ration of 1/1. The  chiral 
derivative of PRO (CL) was chosen to follow the interaction with TNFone utilizing CD in 
the absence of a chiral discriminator. Vibrational CD spectra of CL with TNFone were 
recorded  in  DMSO  d6/D2O  (50:50)  solution,  at  a  concentration  of  0.03  M  with  a 
resolution  of  8  cm‐1,  using  a  Fourier  transform  infrared  (IR)  spectrometer  IFS‐66/S 
(Bruker,  Germany),  equipped  with  a  VCD/IRRAS  module  PMA37  (Bruker).  A 
demountable  cell with CaF2 windows  and  Teflon  spacer of  a 50 µm pathlength was 
used. To  interpret the VCD and  IR spectra of CL with and without TNFone, a possible 
structure  of  the  CL/TNFone  complex was modeled  (see  paper  3,  Fig.  3).  Structure 







Data were  tested  for normal distribution applying  the Kolmogorov‐Smirnov  test and 
histograms. Parametric statistical analyses (ANOVA), followed by the Scheffé post hoc 
test  for  homogenous  or  Dunnet  T3  test  for  non‐homogenous  variances,  were 
performed  on  normally  distributed  data  and  corresponding  non‐parametric  tests 
(Kruskal‐Wallis U‐test) were used  for  skewed data. A p‐value  ≤ 0.05 was  considered 
significant (papers 1, 2, 3, 4, 5). IP0.5 values (percentage of positive control inhibition at 
0.5 µmol TP plate concentration) were used to assess the orders of effectiveness in S. 
typhimurium  tests  and  were  determined  using  the  software  Derive  6  (Texas 
Instruments  Inc.; papers 1, 2, 3). Linear regression slope calculations were completed 
using  Microsoft  Excel  2007,  to  determine  the  orders  of  TP  effectiveness  in  the 
antioxidant  capacity  assays  (paper  2). Relationships  between  variables  (papers  4,  5) 














physiologically  relevant  concentrations  (0.01  –  2  µmol/plate;  3.5  –  714  µM).  In  the 
presence of metabolic activation (S9), the test compounds and mutagens were added 
to Salmonella typhimurium strains TA102 and TA98, to consider different mechanisms 
of mutagenesis. Most  TPs were  clearly  anti‐mutagenic  against  both mutagens, with 
PRO being the most effective compound against AfB1 in strain TA102 and against PhIP 
in  TA98,  followed by  the bilirubinoids. Within  the  TA98‐AfB1  condition, UB was  the 
most effective compound. In all other experiments, the  intestinal compounds UB and 
SB  were  moderately  active.  In  strain  TA98  against  AfB1,  BR  and  BV  exerted  pro‐
mutagenic  responses,  which  were  likely  due  to  their  competition  with  reactive 














A  series  of  newly  tested  (physiologically  relevant)  TPs  were  investigated  in  the 










These data  are  the  first  to  indicate  that UB  and  SB  act  as  antioxidants by donating 
hydrogen atoms to incumbent radical species. This study’s findings show evidence of a 
strong  antioxidant  behavior  of  the  TPs  BR,  BV  and  BRDT  in  the  Salmonella  reverse 
mutation assay, and present  the  first data on an antioxidant activity of BR‐/BV‐DME, 
UB, SB and PRO in vitro. Although in vitro results cannot be directly transferred to the 
in  vivo  condition,  the  data  provide  preliminary  evidence  to  suggest  a  possible 
physiological role of structurally related, partially oxidized TPs, in preventing oxidative 








4.3. Paper  3:  In  vitro  physic‐chemical  properties  of  tetrapyrroles  against 
TNFone‐induced mutagenesis  
(original research article; prepared for submission) 
To  explore  the  physic‐chemical  background  of  TP/mutagen  interaction,  molecular 
systems  of  CL  e6  porphyrin,  BR  and  BV  with  TNFone  were  tested  using  (V)CD 
techniques, which consistently revealed suprastoichiometric anti‐mutagenic effects of 
the considered compounds. Addition of TNFone  to CL e6 porphyrin, BR/albumin and 
BV/albumin  led  to a substantial change  in pigment spectral characteristics, providing 
evidence  for tight TP/mutagen  interactions especially  in the case of protoporphyrin’s 
model  substance.  These  results  are  reflected  in  the  bacterial  model,  in  which  the 




tetrapyrrolic  compounds.  In  that  respect,  the  obtained  novel  evidence  supports 
existing  data  on  an  anti‐mutagenic  activity  of  BR  and  BV  and  possible  underlying 
physic‐chemical  events.  Especially  PRO  continuously  showed  a  remarkable  anti‐











4.4. Paper  4:  Concentration‐dependent  bacterial  bile  pigment  absorption 
and anti‐genotoxic compound effects in vitro  
(short communication; accepted) 
This  study  is  the  first  to  report on bacterial BP  absorption  and  its  relationship with 
observed anti‐mutagenic effects. When exposed to mutagens, extracellular (plate) BP 
concentrations  were  negatively  correlated  to  genotoxicity.  Furthermore,  anti‐
mutagenic testing  in Salmonella strain TA98 revealed that BV and BR absorption was 
more  strongly  related with anti‐mutagenesis, when  compared  to  the anti‐mutagenic 
effect  relative  to  plate  concentrations.  HPLC  analyses  confirmed  that  bacterial  BP 
absorption  was  concentration‐dependent.  Plate  BP  concentrations  were  inversely 
associated with  genotoxicity  of  all  tested mutagens,  irrespective  of  strain  and  test 
conditions.  However,  protection  against  frame‐shift  mutation  in  strain  TA98  most 
strongly depended on the bacterial absorption of BR and BV, which indicates that BPs 
can protect by intercepting mutations extracellularly and specifically inhibit frame‐shift 













4.5. Paper  5:  In  vitro  DNA‐damaging  effects  of  intestinal  and  related 
tetrapyrroles in human cancer cells  
(original research article; under review) 
Epidemiological  studies  report  a  negative  association  between  circulating  bilirubin 
concentrations and  the  risk  for  cancer and  cardiovascular disease.  Furthermore,  few 
data  suggest TPs exert anti‐carcinogenic effects  via  induction of  cell  cycle arrest and 




cytometric  assessment  (apoptosis/necrosis,  cell  cycle,  intracellular  radical  species 
generation) assisted  in  revealing underlying mechanisms of  intracellular  action. Cells 
were incubated with TPs at concentrations of 0.5, 5 and 17 µM for 24 hrs. Addition of 
300 µM tert‐BOOH to cells served as a positive control. Tetrapyrrole incubation mostly 
resulted  in  increased DNA‐damage  (comet  formation)  in Caco2 and HepG2 cells. Test 
compounds that are concentrated within the  intestine,  including PRO, UB and SB,  led 
to significant comet formation in both cell lines, implicating the compounds in inducing 
DNA‐damage and apoptosis in cancer cells found within organs of the digestive system. 
In  summary,  this  study  revealed  substantial  DNA‐damaging  effects  of  tetrapyrrolic 
compounds  in human cancer cells, particularly  for PRO, UB and SB  in HepG2 and  for 
PRO  in  Caco2  cell  lines.  From  this  evidence,  a  chemopreventive  effect  of  the 
compounds might exist within the liver and intestine. Possible underlying mechanisms 
of  DNA‐damage  (e.  g.  including  ROS  formation),  leading  to  cell  cycle  arrest  and 
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toxische  Neben‐  und  Endprodukte  des  Häm‐Katabolismus  betrachtet,  werden  sie 
heute  zunehmend  in  Zusammenhang  stehend  mit  Gesundheitsförderung  und 
Krankheitsprävention gesehen. Daten aus  in  vivo  Studien  legen  vasoprotektive, anti‐
inflammatorische,  anti‐virale  und  anti‐cancerogene  Eigenschaften  nahe,  und  in  vitro 
Experimente  attestieren  Gallenpigmenten  anti‐genotoxische  und  anti‐apoptotische 
Aktivität.  Trotz  solch  vielversprechender  Resultate  bleiben  exakte  zugrundeliegende 
Wirkmechanismen  weitestgehend  unbekannt,  und  sind  Gegenstand  aktueller 
Forschungen.  
Speziell  die  Prävention  weltweit  zunehmender  kardiovaskulärer  Erkrankungen  und 
Krebs,  ist  von  großem  medizinischem  sowie  ökonomischem  Interesse,  und 
unterstreicht  die  Wichtigkeit  fundamentaler  in  vitro  Grundlagenforschung  in  dem 
Bereich.  Speziell  die  Erforschung  natürlicher,  endogen  synthetisierter  Verbindungen 
wie  beispielsweise  des  Bilirubins  bezüglich  seiner  Wirkmechanismen,  stellt  eine 













den  durchgeführten  Tests  zur  anti‐oxidativen  Kapazität  der  Testsubstanzen,  und  es 
zeigte sich im Comet assay DNA‐Schädigung in Krebszellen, was ein toxisches Verhalten 
von Gallenpigmenten in entarteten Zellen im in vitro Modell nahelegt. Diese Resultate 
bestätigen  zum  Einen  bereits  bestehende  Ergebnisse  bezüglich  eines  anti‐
mutagenen/anti‐oxidativen  Potentials  von  Tetrapyrrolen,  und  stellen  zum  Anderen 
durch die Erweiterung der Testbatterie um bislang ungetestete Tetrapyrrole und die 
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Bilirubin exerts physiologically important antioxidant effects and is therefore hypothesised to 
protect against degenerative diseases. Recent in vitro studies also indicate its anti-mutagenic 
action, which is shared by its structurally related precursor, biliverdin. Additional tetrapyrroles, 
concentrated within the gut, were therefore tested for their anti-genotoxic effects in the 
Salmonella reverse mutation assay, in the presence of the food-borne mutagens aflatoxin B1 
(AfB1) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Bilirubin- and biliverdin 
dimethyl esters, naturally abundant un-/conjugated bilirubin, biliverdin, protoporphyrin, urobilin 
and stercobilin were tested within physiologically relevant concentrations (0.01 – 2 µmol/plate; 
3.5 – 714 µM). In the presence of metabolic activation (S9), the test compounds and mutagens 
were added to Salmonella typhimurium strains TA102 and TA98. Most tetrapyrroles were clearly 
anti-mutagenic against both mutagens, with protoporphyrin being the most effective against 
AfB1 in strain TA102 and against PhIP in TA98, followed by the bilirubinoids. Within the 
TA98-AfB1 condition, urobilin was the most effective compound. In all other experiments, the 
intestinal compounds urobilin and stercobilin were moderately active. In strain TA98 against 
AfB1, bilirubin and biliverdin exerted pro-mutagenic responses, which were likely due to their 
competition with reactive mutagens for glucuronidation and detoxification. This study reports 
that intestinally abundant tetrapyrroles prevent genotoxicity induced by poly-/heterocyclic 
amines, which could be specifically important for (gut) health. Furthermore, the data suggest 
unconjugated bilirubin and biliverdin could increase the risk for frame-shift mutation in the 





AfB1: aflatoxin B1; AfM1: aflatoxin M1; AfQ1: aflatoxin Q1; 2-AF: 2-aminofluorene; BP(s): 
bile pigment(s); BR: unconjugated bilirubin; BR-DME: bilirubin dimethyl ester; BRDT: 
bilirubin ditaurate (disodium); BV: biliverdin hydrochloride; BV-DME: biliverdin dimethyl 
ester; BVR: biliverdin reductase; CYP(s): cytochrome P450; DMSO: dimethyl sulfoxide; 
HCA(s): heterocyclic amine(s); HMOX-1: haem oxygenase 1; p-/HCA(s): poly- and 
heterocyclic amine(s); PhIP: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; PRO: 
protoporphyrin IX; SB: stercobilin hydrochloride; S. typhimurium: Salmonella typhimurium; 
TA98/102: Salmonella typhimurium strains TA98 and TA102; TP(s): tetrapyrrole(s); UB: 
urobilin hydrochloride.  
 1. Introduction:  
Aflatoxin B1 (AfB1) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) represent 
food contaminating mutagens derived from nuts, cereals and cooked meat [1, 2]. Upon 
absorption and transport to the liver, the molecules undergo oxidation and glucuronidation by 
cytochrome systems (CYPs) and UDP-glucuronosyltransferases (UGTs) [3], prior to excretion 
in a process commonly referred to as phase-I and -II detoxification. Esterification of 
bioactivated intermediates in the liver represents a key event, limiting the concentration and 
time that the short lived reactive oxygenated molecules can potentially react with DNA [4]. 
Such interaction leads to DNA strand breaks [5], mutation [6, 7] and adduct formation [8, 9], all 
of which are important precursors to malignant transformation, particularly in the liver, biliary 
and gastrointestinal tract [10-14].  
Aflatoxin B1 is metabolized involving CYP1A1, CYP1A2 (formation of exo-/endo-epoxide and 
AfM1) and CYP3A4 (formation of AfQ1 and exo-epoxide [15, 16], which can be found in the 
urine as biomarkers of exposure [17]). Overexpression of CYP1A1/-1A2 after AfB1 exposure is 
documented in cultured human hepatocytes [18]. In the human liver however, previously 
mentioned CYP3A4 predominates and differences in enzyme expression (e.g. CYP3A5) due to 
genetic polymorphisms influence inter-individual AfB1 susceptibility [19, 20]. 
The main cytochrome system involved in PhIP activation is CYP1A2 which transforms the 
compound to its 2-hydroxy-amino intermediate. Subsequent conjugation/esterification by 
sulfotransferase and/or acetyltransferase generates o-sulfonyl or o-acetyl esters [21]. However, 
in humans PhIP metabolism is dominated by glucuronidation (UGT-glucuronosyltransferase 
isoenzymes; UGT1) [22]. The UGT1 complex (especially UGT1A and UGT1B) contributes 
substantially to the biotransformation of PhIP to its main metabolites 2-hydroxy-PhIP and 4’-
hydroxy-PhIP [23, 24].  
 
Importantly, the liver also plays an essential role the metabolism of relevant, potentially 
protective molecules with porphyrin structure [25-28]. For example unconjugated BR [29-32] 
and its derivatives are endogenous haem catabolites formed within the liver and spleen. Haem 
oxygenase (HMOX-1/-2), and NADPH/biliverdin reductase (BLVRA) generate BV and 
subsequently BR, which is glucuronidated in the liver by the UGT1A family [33]. Interestingly, 
deficiency in UGT1A1 activity, as seen in Gilbert’s Syndrome, results in a mildly elevated 
unconjugated hyperbilirubinemia [25-28, 34] and may interfere with xenobiotic metabolism. 
After excretion into the bile, conjugated BR is further metabolized in the gut, forming urobilin 
(UB) and stercobilin (SB), which are re-absorbed or eliminated via the urogenital- (UB) and the 
intestinal tract (SB). Due to their accumulation in the gut, UB and SB could provide protection 
   
from carcinogenesis by physically interacting with food-borne contaminants [35, 36] hindering 
their absorption, or by reacting with oxygenated mutagen intermediates in the liver [28], 
preventing oxidative DNA damage/adduct formation. 
 
Current evidence indicates that elevated blood BR concentrations are strongly associated with 
chemo prevention [37, 38] cardio protection [39, 40], improved glucose tolerance [41], 
beneficial lipid profile, reduced body mass [42], and with a better prognosis in 
neurodegenerative disease [43]. Data mostly on BR and BV support strong multimodal anti-
mutagenic [25, 26] and antioxidant activities of bile pigments (BPs) [44-46] in vitro and in vivo 
[30-32, 46, 47]. Furthermore in vitro anti-carcinogenic properties including pro-apoptotic and 
anti-proliferative protoporphyrin (PRO) effects have been reported [48-50]. Despite these 
findings, the ability of tetrapyrroles (TPs) to inhibit DNA-damage caused by dietary-derived 
mutagens remains unexplored. Revealing inhibitory effects against these agents would represent 
very important contributions to understanding the chemo-preventative effects of BR and related 
TPs in epidemiological studies. Furthermore, by exploring the effects of structurally related 
compounds including BR’s and BV’s dimethyl esters (BR-/BV-DME) would assist in 
understanding the importance of molecular interaction between TPs and mutagens, and the role 
of TP glucuronidation in the bioactivation of pro-mutagens/-carcinogens. Furthermore, with 
significant amounts of UB, SB and PRO within the gut, revealing novel effects of these 
compounds could lead to the development of additional therapeutics to prevent cancer in at-risk-
populations [51].  
 
A few studies have explored the effects of structurally related compounds including 
chlorophyllin, and suggest anti-mutagenic activity through test compound/mutagen complex 
formation [51-54]. The present study aimed to 1) reveal the effects of endogenous TPs on 
AfB1- and PhIP- (dietary-derived) induced mutation, and 2) demonstrate the importance of BP 
physico-chemical structure/competition for phase-II glucuronidation on DNA mutation. 
 
 
2. Materials and methods 
2.1. Salmonella reverse mutation assay:  
 
The Salmonella reverse mutation assay is a well-accepted screening test to evaluate the 
mutagenic potential of chemicals in vitro [55]. Mutagenic substances revert mutated bacteria to 
their wild type variant, which allows them to grow. Genotoxicity (or vice versa anti-genotoxic 
 effects) of compounds can therefore be assessed by quantifying bacterial growth. The 
conducted experiments followed the method of Maron and Ames [56] and included 25 min of 
pre-incubation. S9 liver homogenate (S9 microsomal fraction from Aroclor 1254 pre-treated 
rats) was used as an enzymatic activation system in all of the assays. 
 
2.1.1. Chemicals:  
Bilirubin IXα (BR) [CAS# 635-65-4], bilirubin conjugate (ditaurate) disodium (BRDT) [CAS# 
635-65-4], biliverdin IXα (BV) [CAS# 55482-27-4], bilirubin dimethyl ester (BR-DME) [CAS# 
19792-68-8], biliverdin dimethyl ester (BV-DME) [CAS# 10035-62-8], protoporphyrin IX 
(PRO) [CAS# 553-12-8] as well as urobilin (UB) [CAS# 28925-89-5] and stercobilin (SB) 
[CAS# 34217-90-8] were purchased from Frontier Scientific, UK. Compound purity (> 98 %) 
and solubility were assessed using high pressure liquid chromatography (HPLC) and 
spectrophotometry. The S9 liver homogenate was from MP Biomedicals, Illkirch (France). All 
other reagents were from Sigma Aldrich Austria (unless otherwise noted), were of the highest 
analytical grade available and were stored and used according to instructions. 2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine was purchased from Toronto Research Chemicals, 
Canada). Test compounds (supplementary material 1) were solubilised in DMSO (CAS# 67-68-
5) were protected from light using foil, and used immediately. Composition and preparation of 
all necessary reagents and solutions can be found elsewhere [26].  
 
2.1.2. Bacterial strains:  
S. typhimurium strains were obtained from Dr. Bruce N. Ames (University of California, 
Berkley, USA). Frozen permanents were stored at -80 °C until use. Prior to the tests being 
conducted, the strains were attested to their genetic integrity and spontaneous mutation rate 
[55]. Two distinct strains were adopted to consider multiple mechanisms of protection from 
mutation: the DNA repair proficient strain TA102 (hisG428 mutation), detecting A/T base pair 
damage and small deletions provoked by cross-linking agents, can be reverted by mutagens 
causing oxidative damage, and TA98 (hisD3052 mutation) primarily detecting G/C base pair 
and frame-shift mutations. The Salmonella strains used in the experiments have different 
mutations in various genes in the histidine operon; each of these mutations is designed to be 
responsive to mutagens that act via different mechanisms [55].  
 
   
2.1.3. Sample preparation:  
Following preceding experiments [26] and a series of solubility assays, six doses of BRDT, 
BV and previously untested BR-DME, BV-DME, UB, SB and PRO were investigated at 0.01, 
0.05, 0.1, 0.5, 1 and 2 µmol/plate (3.5 µM – 714 µM). Bilirubin was tested over a range of five 
doses including: 0.01, 0.05, 0.1, 0.5 and 0.75 µmol/plate (3.5 µM – 268 µM). The respective 
maximum sample doses had been ascertained by 1) testing the maximum amount of DMSO that 
did not result in bacterial cytotoxicity (350 µl/plate, approx.. 12 % v/v) and 2) by the respective 
maximum solubility of each compound (supernatant analysis via spectrophotometry: BR, 
BRDT, BR-DME: 455 nm; PRO: 410 nm; UB, SB: 400 nm; BV, BV-DME: 380 nm; read on a 
Perkin Elmer Lambda 2 UV/VIS spectrophotometer after high-speed centrifugation; HPLC 





2.1.4. Positive and negative controls:  
 
Table 1. Positive controls in use. DMSO served as a negative control.  
Compound Occurrence Class Solvent Strain(s) Conc. [mol/plate] S9^ 
Aflatoxin B1 (AFB1)  
 
Food borne (agricultural 
produce, nuts, cereals) [19] 




0.8 x 10-7 





b]pyridine (PhIP)  
 
Food borne; high 
temperature cooking of 
meat [40, 41]. Alternative 




structure [73]; mutagen 
DMSO TA98 0.1 x 10-7 + 
 





2.2. Experimental design:  
The assays were performed in a dimly lit laboratory under sterile working conditions (Laminar 
airflow cabinet Safemate 1.8; Bioair Euroclone, Italy). Samples were protected from light 
throughout the experiments and were freshly prepared in amber vials before each test. 500 µl of 
PBS buffer or S9-mix (19.75 ml dH2O, 25 ml PBS buffer, 500 µl MgCl2 (0.85 M), 0.5 ml KCl 
(1.65 M) and 2 ml NADP (90.8 mM), 250 µl glucose-6-phosphate (1.08 M) and 2 ml of S9.), 
100 µl of overnight culture, 200 µl of TP solution (in DMSO) were merged in sterile test tubes. 
For anti-mutagenic testing 100 µl of mutagen (in DMSO or DMSO alone for controls) were 
added to each tube (Table 1). After 25 mins of pre-incubation (37 °C, on rotary-shaker) 2 ml of 
molten top agar were added to every tube. The mixtures were poured onto minimum glucose 
agar plates which were incubated at 37 °C for 48 hrs. His+ revertants were counted manually 
after having routinely checked the background lawn under a microscope (40 x magnification; 
Olympus CH-2). DMSO final plate concentrations did not exceed 10 % v/v.  
Each sample was tested in triplicate and all of the assays were independently repeated again. 
Every test included three “positive control plates” (mutagen only) and six “negative control 
plates” (no mutagen, no pigment) as well as three “no treatment plates” (no mutagen, no 
pigment, no DMSO).  
For a substance to be classified genotoxic in the Salmonella reverse mutation assay, the 
number of revertant colonies on the test compound plates had to exceed twice the number of 
colonies grown on the solvent control plates (negative control) [55].  
In addition to investigating the anti-mutagenic effects of TPs, the compounds’ spontaneous 
mutagenic activities were tested; for each sample the respective highest and lowest 
concentrations were applied without mutagen addition. None of the tested samples caused 
mutagenesis in either of the bacterial strains (p ≥ 0.05). 
 
2.3. Statistical analysis:  
Data were analyzed using IBM SPSS 17.0 for Windows. A p-value ≤ 0.05 was considered 
significant. All data are presented as mean ± SD. Data were tested for normal distribution 
(Kolmogorov-Smirnov test). Parametric statistical analysis (one-way analysis of variance, and 
the Scheffé post hoc test) were performed on normally distributed data and corresponding non-
parametric tests (Kruskal-Wallis test, Dunnet T3 post hoc test) on not normally distributed data. 
To assess the order of effectiveness of the tested compounds, data were analyzed using IP0.5 





3.1. AfB1-induced mutagenesis in strain TA102 
 
Bilirubin, BRDT and BR-DME all significantly lowered AfB1-induced mutagenic effects (p < 
0.01). Within this compound group BRDT was most effective (Fig 1A).  
As presented in Fig 1B, both BV and its methyl ester derivative significantly lowered revertant 
counts versus positive control (p < 0.001), with BV being most effective.  
PRO was the most effective of all tested compounds in TA102 (Fig 1C). In a dose-dependent 
manner it significantly lowered revertant counts versus positive control (p < 0.001). Urobilin 
attenuated AfB1-induced mutation in a dose-dependent manner, with all tested concentrations 
indicating significant anti-mutagenic effects (p < 0.05). For SB, an anti-mutagenic tendency 
without dose-dependency was observed. At 0.01, 0.05, 0.1, 0.5 and 1 µmol/plate, SB reduced 
the number of revertants significantly versus positive control (p < 0.05). The overall order of 
effectiveness based on IP0.5 values was calculated as follows (see Table 2): PRO > BR = 































Figure 1A–C. Anti-mutagenic effects of A) BR, BRDT, BR-DME; B) BV, BV-DME and C) UB, SB, 
PRO against metabolically activated AfB1-induced mutagenesis in Salmonella typhimurium strain 
TA102. 
BR: unconjugated bilirubin, BRDT: bilirubin ditaurate (conjugated bilirubin), BR-DME: bilirubin 
dimethyl ester, BV: biliverdin, BV: biliverdin dimethyl ester, UB: urobilin, SB: stercobilin, PRO: 





3.2. AfB1-induced mutagenesis in strain TA98 
In contrast to TA102 results, neither BR nor BRDT acted in an anti-mutagenic manner in strain 
TA98, and increased revertant formation significantly (p < 0.001). However, a significant anti-
mutagenic behavior was found over the entire range of BR-DME concentrations (p < 0.001; Fig 
2A).  
As presented in Fig 2B, a similar observation indicated that BV significantly increased revertant 
formation, whereas its esterified counterpart was significantly anti-mutagenic versus positive 
control (p < 0.001), at all concentrations.  
Urobilin was the most anti-mutagenic of all tested compounds (Fig 2C). At all concentrations, 
UB significantly lowered AfB1-induced mutagenesis by up to 75 % (p < 0.05). At 1, 2 and 0.5 
μmol/plate PRO also lowered revertant counts compared to positive control values. As for SB, 
significant anti-mutagenic effects at all concentrations (except for 2 μmol/plate) were reported 
(p < 0.05). However, the observed effects were not dose-dependent. The overall order of 
effectiveness based on IP0.5 values was calculated as follows (see Table 2): UB > BV-DME > 
BR-DME > SB > PRO. Bilirubin ditaurate, BR and BV did not attenuate AfB1-induced 
mutagenesis in this condition.  
 
3.3. PhIP-induced mutagenesis in TA98 
Bilirubin, BRDT and BR-DME (Fig 3A) were highly effective against PhIP-induced 
mutagenesis when compared to positive control values (p < 0.001). All samples attenuated 
PhIP-induced mutagenesis by over 60 % and appeared equally effective.   
A strong dose-dependent effect was noted for BV but not for BV-DME (Fig 3B). However, both 
compounds significantly lowered revertant counts over the entire concentration range versus 
positive control (p < 0.001).  
Both, SB and UB were significantly effective at all tested doses (p < 0.05) and showed strong 
anti-mutagenic effects towards PhIP-induced genotoxicity. Protoporphyrin significantly lowered 
PhIP-induced effects by more than 90 %, resulting in a nearly complete PhIP detoxification (p < 
0.001). In addition, strong concentration-dependent effects were seen with all of the tested 
compounds (Fig 3C). The overall order of effectiveness was calculated as follows (see Table 2): 






























Figure 2A–C. Anti-mutagenic effects of A) BR, BRDT, BR-DME; B) BV, BV-DME and C) UB, SB, 
PRO against metabolically activated AfB1-induced mutagenesis in Salmonella strain TA98.  
BR: unconjugated bilirubin, BRDT: bilirubin ditaurate (conjugated bilirubin), BR-DME: bilirubin 





























Figure 3A–C. Anti-mutagenic effects of A) BR, BRDT, BR-DME; B) BV, BV-DME and C) UB, SB, 
PRO against metabolically activated PhIP-induced mutagenesis in Salmonella strain TA98.  
BR: unconjugated bilirubin, BRDT: bilirubin ditaurate (conjugated bilirubin), BR-DME: bilirubin 
dimethyl ester, BV: biliverdin, BV: biliverdin dimethyl ester, UB: urobilin, SB: stercobilin, PRO: 





Table 2. Anti-mutagenic behaviour of tetrapyrroles against metabolically activated 









(p ≤ 0.05)# 
His+pos  
± SD^ 






1142 ± 112 
   BRDT - 54 BV-DME, UB, SB, PRO 
   BR-DME - 45 BR, BRDT, BV, BV-DME, UB, 
PRO 
   BV - 52 BR-DME, BV-DME, UB, SB, 
PRO 
   BV-DME - 27 BR, BRDT, BR-DME, BV, BV-
DME, UB, SB, PRO 
   UB - 42 BR, BRDT, BR-DME, BV, BV-
DME, PRO 
   SB - 43 BR, BRDT, BV, BV-DME, 
PRO 
   PRO - 68 BR, BRDT, BR-DME, BV, BV-
DME, UB, SB, PRO 
TA98 AFB₁ 0.8 x 10-7 + BR + 352 BRDT, BR-DME, BV-DME, 








318 ± 26 
   BRDT  + 268 BR, BR-DME, BV, BV-DME, 
UB, SB, PRO 
   BR-DME - 45 BR, BRDT, BV, BV-DME, UB, 
SB, PRO 
   BV + 363 BRDT, BR-DME, BV-DME, 
UB, SB, PRO 
   BV-DME - 59 BR, BRDT, BR-DME, BV, UB, 
SB, PRO 
   UB - 79 BR, BRDT, BR-DME, BV, BV-
DME, SB, PRO 
   SB - 37 BR, BRDT, BR-DME, BV, BV-
DME, UB, PRO 
   PRO - 11 BR, BRDT, BR-DME, BV, BV-
DME, UB, SB 
TA98 PhIP 0.1 x 10-7 + BR - 82 BRDT, BR-DME, BV-DME, 








789 ± 77 
   BRDT  - 64 BR, BR-DME, BV, BV-DME, 
UB, SB, PRO 
   BR-DME - 68 BR, BRDT, BV, BV-DME, UB, 
SB, PRO 
   BV - 78 BR, BRDT, BR-DME, BV-
DME, UB, SB, PRO 
   BV-DME - 55 BR, BRDT, BR-DME, BV, UB, 
PRO 
   UB - 48 BR, BRDT, BR-DME, BV, BV-
DME, SB, PRO 
   SB - 57 BR, BRDT, BR-DME, BV, UB, 
PRO 
   PRO - 97 BR, BRDT, BR-DME, BV, BV-
DME, UB, SB 
 
BR: unconjugated bilirubin, BRDT: bilirubin ditaurate, BR-DME: bilirubin dimethyl ester, BV: 
biliverdin, BV-DME: biliverdin dimethyl ester, UB: urobilin, SB: stercobilin, PRO: protoporphyrin. 
AfB1: aflatoxin B1, PhIP: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. °IP0.5: Percentage positive 
control inhibition at 0.5 µmol/plate (highest common sample dose per plate): “-“ indicates mutagen 
attenuating effect, “+”amplifying effect; ^His+pos: average positive control revertant counts ± SD. #based 





The current study demonstrates BR and structurally related TPs exert anti-mutagenic/anti-
oxidant effects, preventing mutation caused by the food-derived mutagens AFB1 and PhIP. 
Protoporphyrin was highly effective against AfB1- and PhIP-induced mutagenesis in both 
Salmonella strains, followed (in effectiveness) by TPs containing rubinoid structure. The 
calculated orders of effectiveness based on IP0.5 values were: PRO > BR = BRDT > BV > BR-
DME > SB > UB > BV-DME for AFB1 in strain TA102, UB > BV-DME > BR-DME > SB > 
PRO for AfB1 in strain TA98, and PRO > BR > BV > BR-DME > BRDT > SB > BV-DME > 
UB for PhIP in the TA98 strain.  
To date the possible mechanisms of TP protection from mutation are not fully understood. 
Furthermore, the ability of TPs to inhibit DNA-damage caused by dietary-derived mutagens, 
remains entirely unexplored. In consideration of the different bacterial strains and the mutagens 
that were used, multiple anti-mutagenic mechanisms must be considered. Salmonella strain 
TA102 reverts upon exposure to oxidation, whereas the TA98 strain mutates upon interaction 
with mutagens.  
 
AfB1-induced mutagenesis: 
So far, physico-chemical studies suggest that both aromatic and planar AfB1 characteristics 
allow for TP complex formation, inhibiting covalent AfB1 interaction with DNA. In vitro 
studies investigating the anti-mutagenic effects of chlorophyllin and related porphyrins show 
strong non-covalent complex formation with toxins that bear planar and aromatic structures [63-
65]. Therefore, complex formation is routinely used as a method to detect polycyclic 
compounds in foodstuffs [54]. Similarly, in vivo data imply complex formation between 
chlorophyllins and food-borne mutagens in the gut followed by electrophile scavenging and 
complexing in the target organ [66, 67]. Thus, chlorophyllin and structurally related pigments 
including the compounds tested here, are expected to inhibit carcinogen-DNA binding in vivo, 
and consequently prevent DNA damage [52, 53], particularly in the intestinal tract, the primary 
location of food-derived mutagen accumulation. Dashwood et al. (1995) proposed the exocyclic 
amine group of poly- and heterocyclic mutagens consistently bind to acidic groups in 
chlorophyllin [51]. If that structural anti-mutagenic hypothesis also applies to other porphyrins, 
it is likely that BR, BV, SB and UB would also effectively inhibit these mutagens, due to their 
free carboxylic acid groups. This conclusion was in part confirmed in the strain TA102 test 
condition (Figure 1A – C), in which the compounds carrying free carboxylic groups were 
among the most effective against AfB1. However, test compound behaviour was somewhat 




unexpectedly showed elevated revertant counts (associated with a pro-mutagenic potential). 
Clearly, free carboxylic acid groups were instrumental to this response, because their methyl 
ester derivatives acted in a reliable anti-genotoxic manner in both tester strains.  
A mechanistic explanation for the observed contradictory results could include AfB1-adduct 
formation at guanine bases in bacterial DNA [68], which the TA98 strain is particularly prone 
to. This would result in pronounced AfB1-induced mutagenesis specifically in this strain. 
Furthermore this strongly supports a role for BR-/BV-DME in anti-mutagenesis, which were 
clearly effective in TA98. This was very much in contrast to their non-methylated free acidic BR 
and BV counterparts, as can be seen from Figure 2A - C. The esterified compounds retained 
their anti-mutagenic effectiveness also in strain TA102. The most likely explanation for BR’s 
and BV’s strong pro-mutagenic effects probably implicates their phase-II metabolism which 
results in their glucuronidation [69]. Reactive AfB1 intermediates could potentially compete 
with the same metabolic pathway, increasing the concentration of reactive epoxide, prior to any 
detoxification/glucuronidation. In contrast, BR-/BV-DME could not be conjugated, and thus 
would not represent UGT1A substrates, allowing for secondary AfB1 metabolism to stable 
glucuronides [36]. These data (Figures 2A and 2B) strongly indicate that carboxylic acid groups 
on BR and BV molecules are associated with an increase in mutation, which might compete 
with AfB1 for phase-II detoxification.  
Followed by BR, PRO was the most effective agent against AfB1 in strain TA102, which 
confirms the compounds’ potent antioxidant activity, seen previously against tert-BOOH-
induced mutagenesis. The same study suggested PRO as a potent reducing agent due to its 
extended π-electron system, which enabled considerable electron donation [28], allowing for 
substantial covalent binding capacity with biomolecules [70, 71]. This strongly supports a role 
for PRO in inhibiting AfB1-induced mutagenesis by direct interaction with the mutagen, 
consequently preventing oxidative damage. Protoporphyrin was moderately effective against 
AfB1 in strain TA98, further supporting the possibility of physico-chemical interaction between 
them.  
 
PhIP-induced mutagenesis:  
The possibility of PhIP and PRO interaction, leading the inhibition of mutation was also 
reported in the present study. As previously observed in the presence of AfB1 (especially in 
strain TA102), PRO was the most effective anti-mutagen also within the TA98-PhIP experiment, 
which under certain test conditions indicates that PRO is a potent inhibitor of frame-shift 
mutations at concentrations that exist within the intestine (0.2 – 14 µM [72]). Frame-shift 




cancer [73, 74]. Therefore, these results could be of great importance in explaining a possible 
role for intestinal PRO in preventing gastro-intestinal carcinogenesis. This is supported by a 
preceding study (in which PRO was not considered) [27]: BR and BV bacterial absorption 
strongly protected against frame-shift mutation in the TA98 strain. It was speculated that the 
affinity of BPs to protect against frame-shift mutation, might partly explain the protective 
relationship between serum BR levels and colorectal cancer in vivo [38].  
 
5. Conclusion  
In summary, these data report that intestinally abundant TPs (UB, SB, PRO) prevent 
genotoxicity induced by dietary-derived mutagens, which could be specifically important for 
gut health. The TPs’ mechanisms of anti-genotoxic action might include either direct interaction 
with mutagens (relevant to strain TA98 data) or via their antioxidant effects (in strain TA102). 
Furthermore, the data implicate elevated levels of unconjugated BR and BV could increase the 
risk for frame-shift mutation in the presence of AfB1, by possibly competing for phase-II 
detoxification. 
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diseases  in vivo. Therefore, testing TPs in terms of their 
antioxidant capacity  in vitro would provide essential infor-
mation on their potential to reduce oxidation processes 
and subsequent damage to cells. 
 When examining redox processes within human cell 
systems, reactive oxygen and nitrogen species (ROS, 
RONS) possess both potentially beneﬁ cial and detrimental 
eﬀ ects. When produced in excess, radical species can 
damage DNA, lipids and proteins, and may thereby con-
tribute to the pathogenesis of cancer and heart diseases 
[10]. Unconjugated BR represents an important defense 
against oxidative stress  in vivo [12].  In vitro studies dem-
onstrate that BR scavenges singlet oxygen [13] and serves 
as a reducing agent for certain (hydro-)peroxides [14]. 
Also, a number of other RO(N)S can be scavenged by BPs 
[15], suggesting that BR and BV act similar to vitamin C 
and scavenge both 1e    and 2e    oxidants [16]. Similar to 
many physiological antioxidants, BR and BV protect 
membrane lipids from oxidation by acting in synergy with 
membrane incorporated  α -tocopherol [17]. These eﬀ ects 
are enhanced when BR is albumin-bound [18], which ﬁ xes 
the compound in an out-of-plane conformation, beneﬁ cial 
for H-abstraction by radical species [19]. Despite already 
proven antigenotoxic eﬀ ects of BR, BV and BRDT against 
multiple classes of mutagens [5 – 7], comparatively little is 
known about the antigenotoxic capacity of structurally 
related physiological TPs. For example, the antioxidant 
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 Abstract 
 The antioxidant properties of protoporphyrin IX and related tetrapyrroles are poorly characterized. Therefore, eight tetrapyrroles, ﬁ ve of 
which are produced  in vivo, were tested to assess their antioxidant capacities in the  Salmonella reverse mutation, TEAC, FRAP and ORAC 
assays. Tertiary-butyl hydroperoxide ( tert- BOOH) in the presence or absence of metabolic activation (  S9) was added to  Salmonella strain 
 TA102 together with the test compounds. In the absence of metabolic activation, the order of eﬀ ectiveness was protoporphyrin   biliverdin 
  bilirubin ditaurate   bilirubin   biliverdin dimethyl ester   stercobilin   bilirubin dimethyl ester   urobilin. In the presence of S9, 
the eﬀ ectiveness was reversed, with urobilin   biliverdin dimethyl ester   bilirubin dimethyl ester   stercobilin   biliverdin   bilirubin 
  bilirubin ditaurate   protoporphyrin. In the antioxidant capacity assays FRAP, TEAC and ORAC, mainly bilirubin, bilirubin ditaurate, 
biliverdin and protoporphyrin showed antioxidant activity. This study reports that previously untested tetrapyrroles of related structure 
prevent oxidatively induced genotoxicity, and for some, novel underlying mechanisms of antioxidant action were revealed. These results 
support the physiological importance and biological relevance of tetrapyrroles including protoporphyrin that might act as antioxidants, 
protecting from oxidatively induced DNA damage, particularly in the tissues/organs where they accumulate. 
 Keywords:  bilirubin ,  urobilin ,  stercobilin ,  Salmonella ,  tert-BOOH 
 Introduction 
 Bile pigments (BPs) are endogenously formed tetrapyr-
rolic dicarboxylic acids with porphyrin structure derived 
from the enzymatic heme degradation [1], which gener-
ates both pro- and antioxidant compounds [2], and liber-
ates biliverdin (BV), carbon monoxide and free iron [3]. 
Subsequently, biliverdin reductase (BLVRA) reduces BV 
to unconjugated bilirubin (BR) which is glucuronidated 
and excreted from the body in the bile. The BR metabo-
lites, urobilinogen and urobilinoids, are exclusively found 
in the intestinal- (urobilin, UB and stercobilin, SB) and 
the urinary tract (urobilin) [4], where they could contrib-
ute to health promotion. So far, the scientiﬁ c focus has 
mostly been directed towards the antigenotoxic properties 
of BV and BR  in vitro [5 – 7], their  in vivo and  ex vivo 
antioxidant eﬀ ects [8 – 10] and chemopreventive potential 
[11]. However, the eﬀ ects of structurally related tetrapyr-
roles (TPs) have rarely been investigated. Therefore, the 
antioxidant/antigenotoxic potential of many of the com-
pounds studied here ( e. g. protoporphyrin (PRO), UB and 
SB) remain unknown. Furthermore, possible eﬀ ects of 
structural modiﬁ cations to BR and BV on antimutagen-
icity have not yet been investigated, which might provide 
mechanistic insight regarding their protective properties. 
Reduction of oxidative stress through TP antioxidant 
action could play a key role in lowering the risk for certain 
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capacity of urobilinoids is only described by Nakamura 
and colleagues [20], who compared  i- urobilinogen in 
terms of its 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical 
scavenging activity to other known antioxidants such as 
BR,  a -tocopherol and  ß -carotene. Among those com-
pounds tested,  i -urobilinogen most potently inhibited 
free radical-induced lipid oxidation [20]. The potential of 
UB and SB remain unexplored. 
 The antioxidant eﬀ ects of BR and BV dimethyl esters 
(BR-/BV-DME), were exclusively investigated by McLean 
[21], Chepelev [22] and colleagues, who concluded that 
hydrogen atom transfer, proton-coupled electron transfer 
and single electron transfer are possible mechanisms of 
antioxidant action. Despite these ﬁ ndings, it is unknown 
whether these compounds retain the antigenotoxic capacity 
of BV and unconjugated BR. 
 From the little available data on PRO,  in vitro evidence 
suggests that the compound exerts antioxidant capacity in 
the absence of light; however, its relative activity com-
pared to other TPs, remains unknown [23]. Testing these 
eﬀ ects is important because heme is catabolized to a num-
ber of molecules containing a conjugated system of double 
bonds  in vivo , including PRO, BV, BR, UB and SB. To 
understand the possible physiological importance of these 
molecules, it is ﬁ rst essential to describe their in vitro 
antioxidant activities, using assays that test diﬀ erent 
mechanisms of radical reduction. 
 In summary, the antioxidant/antigenotoxic activity of a 
small selection of heme catabolites has been investigated 
so far. Therefore, this study aimed to test the antigenotoxic 
potential of ﬁ ve novel TPs and discuss mechanisms 
behind their antioxidant activity by applying multiple 
in vitro assays. These data will assist in understanding 
their potential beneﬁ cial activities in terms of disease 
prevention. 
 Materials and methods 
 Salmonella reverse mutation assay 
 The  Salmonella reverse mutation assay is a screening 
test to evaluate the anti/mutagenic potential of chemicals 
 in vitro , and is based on mutagen-induced bacterial wild 
type reversion. Data were generated as previously pub-
lished [24]. S9 liver homogenate (S9 microsomal fraction 
from Aroclor-treated rats) was applied as an enzymatic 
activation system in speciﬁ ed experiments. 
 Chemicals. Bilirubin IX a (BR) [CAS# 635-65-4], biliru-
bin conjugate (ditaurate) disodium (BRDT) [CAS# 
635-65-4], biliverdin IX a (BV) [CAS# 55482-27-4], bili-
rubin dimethyl ester (BR-DME) [CAS# 19792-68-8], 
biliverdin dimethyl ester (BV-DME) [CAS# 10035-62-8], 
protoporphyrin IX (PRO) [CAS# 553-12-8] as well as uro-
bilin (UB) [CAS# 28925-89-5] and stercobilin (SB) [CAS# 
34217-90-8] were purchased from Frontier Scientiﬁ c, UK. 
Chemical structures of the test compounds can be found 
in the supplementary section  (Supplementary material 1 
to be found online at http://informahealthcare.com/doi/
abs/10.3109/10715762.2012.715371). The S9 liver homo-
genate was purchased from MP Biomedicals, France. All 
other reagents and mutagens were obtained from Sigma 
Aldrich, Austria (unless otherwise noted), were of the 
highest analytical grade available and stored according to 
instructions. Throughout the test procedures all test 
compound solutions (DMSO) were protected from light 
using foil. Composition and preparation of all necessary 
solutions can be found elsewhere [6]. 
 Bacterial strain. Salmonella typhimurium (S. typhimu-
rium) strain  TA102 was kindly provided by Dr. Bruce N. 
Ames and stored as frozen permanents at   80 ° C until use. 
Prior to the tests being conducted, the strain was attested 
to its genetic integrity and spontaneous mutation rate [25] 
in our laboratory. To test for the pigments ’ ability to pre-
vent oxidative DNA damage, the DNA repair proﬁ cient 
strain  TA102 was selected. This strain detects A/T base 
pair damage and deletions provoked by cross-linking 
agents and can be reverted by mutagens that cause oxida-
tive damage, for example through the production of free 
radicals [25]. 
 Tetrapyrrole sample preparation. Based upon preceding 
experiments [6], six doses of BRDT, BV and PRO (0.01, 
0.05, 0.1, 0.5, 1 and 2  μ mol/plate) were applied in the 
present study to encompass their physiologically relevant 
concentration range. Bilirubin and previously untested 
UB, SB and BR-/BV- dimethyl esters (BR-DME, BV-
DME) were tested up to 0.75  μ mol/plate (due to solubility 
limitations). Maximum doses had been ascertained by 
(1) testing the maximum amount of DMSO that did not 
result in bacterial toxicity and (2) by the respective maxi-
mum solubility of each compound (supernatant analysis 
conducted photometrically at 380 and 450 nm; HPLC 
analysis after high-speed centrifugation). DMSO toxicity 
was monitored by screening the background lawn 
present on minimal glucose agar plates after addition 
of increasing amounts of DMSO (0 – 500  μ l). The applied 
positive control/mutagen was synthetic, organic tertiary-
butyl hydroperoxide ( tert- BOOH; Merck, Austria), diluted 
in dH 2 O and used at a concentration of 0.75   10   6  mol/
plate. DMSO served as negative control. 
 Experimental design. All assays were performed under 
light exclusion and sterile working conditions (Laminar 
airﬂ ow cabinet Safemate 1.8; Bioair Euroclone, Italy). 
Before each test, all stock TP solutions and diluted sam-
ples were freshly prepared. 500  μ l of 1  PBS buﬀ er or 
S9-mix, respectively (19.75 ml dH 2 O, 25 ml PBS buﬀ er, 
0.5 ml MgCl 2 (0.85 M), 0.5 ml KCl (1.65 M) and 2 ml 
NADP (90.8 mM), 250  μ L glucose- 6 -phosphate (1.08 M) 
and 2 ml of S9), 100  μ l of overnight culture, 200  μ l of BP 
solution (in DMSO) were mixed in sterile glass tubes. For 
antimutagenic testing 100  μ l of mutagen (in DMSO or 
DMSO alone for controls) was added to each tube. After 
25 minutes of pre-incubation (37 ° C, on rotary-shaker), 
2 ml of molten top-agar was added to every tube. The 
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mixtures were poured onto minimum glucose plates, fol-
lowed by 48 hrs of incubation at 37 ° C. Bacterial colonies 
(His    revertants) were counted manually after having rou-
tinely checked the background lawn under a microscope 
(Olympus CH-2; 40x magniﬁ cation). 
 As recommended in the literature, each sample concen-
tration was tested in triplicate, with positive and negative 
controls tested six times, with all assays performed twice 
[6,24 – 26]. For a substance to be considered genotoxic in 
the  Salmonella reverse mutation test, the number of rever-
tant colonies on the test compound plates has to exceed 
twice the number of colonies produced on the solvent 
control plates (negative control) [25]. 
 Besides investigating antimutagenic eﬀ ects of TPs, 
spontaneous mutagenic eﬀ ects were also tested for each 
compound. The respective highest and lowest doses of 
each compound were applied without mutagen addition. 
 Measures of antioxidant capacity 
 To assess the antioxidant/reducing powers of the test 
compounds, the trolox equivalent antioxidant capacity 
(TEAC), oxygen radical absorbance capacity (ORAC) and 
the ferric reducing antioxidant potential assays (FRAP) 
were conducted as the most popular methods published in 
the international literature [27 – 29]. Tetrapyrrole stock 
solutions were prepared in DMSO at concentrations of 
2.5, 0.75, and 0.25 mM for BV and BRDT, and 0.75, 0.5 
and 0.25 mM for the remaining compounds, due to solu-
bility limitations, which had been assessed spectrophoto-
metrically (refer to paragraph 2.1.3.). 
 In the TEAC assay, oxidation of 2,2  -azino-bis(3-
ethylbenzoathiazoline-6-sulfonic acid), ABTS is initiated 
by persulphate, forming the ABTS radical. The ability of 
the test compound to reduce this radical is measured 
spectrophotometrically as published previously [30]. 
 The ORAC assay is based on the inhibition of the 
peroxyl-radical induced oxidation which is triggered 
by thermal decomposition of the azo-compounds 2,2  -
azo-bis(2-amidino-propane dihydrochloride) AAPH. Over 
time, radicals generated from this decomposition, quench 
the ﬂ uorescein signal. Subsequent antioxidant addition 
stabilizes the ﬂ uorescence signal, which is expressed rela-
tive to trolox equivalents. Measurements were performed 
as previously published [31]. 
 In the FRAP assay, reduction of the ferric tripyridyltri-
azine complex (Fe 3   ) to the ferrous complex (Fe 2   ) in the 
Fe 3   /Fe 2   TPTZ redox system, is measured at pH 3.6. 
Change in absorbance is directly related to the nonthiol 
reducing power of antioxidants present in the sample. 
Absorbance was measured as previously published [27]. 
 Statistical analysis 
 All data were analyzed using SPSS 17.0. Data were tested 
for normal distribution by applying the Kolmogorov-
Smirnov test and histograms. Parametric statistical analy-
ses (ANOVA), followed by the  post hoc Scheﬀ  é or Dunnet 
T3 tests, were performed on normally distributed data and 
corresponding nonparametric tests (Kruskal-Wallis H-test) 
were used for skewed data. A  p- value    0.05 was consid-
ered signiﬁ cant. IP 0.5 values (percentage of positive control 
inhibition at 0.5  μ mol TP plate concentration) were used 
to assess the orders of eﬀ ectiveness in  S. typhimurium tests, 
and were determined using Derive 6 (Texas Instruments 
Inc.). A variety of curve algorithms were ﬁ tted to the data 
using Micrsoft Excel 2007 (linear, logarithmic, polyno-
mial, exponential) and in every instance the algorithm with 
the highest R 2 value was chosen [6]. IP 0.5 values were inter-
polated from these algorithms using Derive 6 to determine 
the orders of TP eﬀ ectiveness in the reverse mutation 
assays and antioxidant capacity assays. Besides, IC 75 val-
ues were calculated to assess test compound concentrations 
( μ mol/plate) needed to attenuate positive control eﬀ ects by 
25%. 
 Results 
 Bilirubin, BV, BRDT, UB, SB, and BR-/BV-DME were 
tested in  S. typhimurium strain  TA102 to assess their 
potential to modulate spontaneous or induced oxidative 
DNA damage. In the absence of  tert -BOOH none of 
the tested compounds caused toxicity or mutagenesis 
(p    0.05; data not shown). 
 Prevention of oxidative stress-induced mutagenesis 
 tert-BOOH-induced oxidation (S9). Protoporphyrin was 
the most active compound of those tested, and inhibited 
35% of  tert- BOOH-induced oxidative damage (Figure 1A). 
All PRO doses yielded signiﬁ cant dose dependent reduc-
tions in revertant counts compared to positive control val-
ues ( p  	  0.05) . In contrast, UB and SB failed to signiﬁ cantly 
reduce the number of revertant colonies and UB showed 
no dose-dependent eﬀ ect (Figure 1A) . Also BV from 0.5 
to 2  μ mol/plate signiﬁ cantly and dose-dependently low-
ered revertant colony growth compared to positive control 
values ( p  	  0.05, Figure 1B), similar to BV-DME at 1 and 
0.1  μ mol/plate ( p  	  0.05, Figure 1B) . 
 Unconjugated bilirubin at 0.75  μ mol/plate tended to 
lower  tert- BOOH-provoked oxidative stress, and inhibited 
20% of the induced damage. Bilirubin dimethyl ester sig-
niﬁ cantly lowered revertant counts at 1 and 0.5  μ mol/plate 
compared to positive control values ( p  	  0.05) . All concen-
trations of BRDT, except for 0.01  μ mol/plate signiﬁ cantly 
decreased colony formation in a dose-dependent manner, 
compared to positive control ( p  	  0.01, Figure 1C) . 
 For comparison, the percentage positive control inhibi-
tion of each pigment at 0.5  μ mol/plate (IP 0.5 ) was calcu-
lated (Table I) . From these percentages, the order of TP 
eﬀ ectiveness (based on IP 0.5 ) in the absence of S9 was 
determined as follows: PRO   BV   BRDT   BR   
BV-DME   SB   BR-DME   UB. 
 tert-BOOH-induced oxidation (  S9). With metabolic acti-
vation, results for PRO and UB were reversed: PRO was 
ineﬀ ective whereas UB and SB signiﬁ cantly attenuated 
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 Antioxidant capacity of tetrapyrroles 
 Considering the test compound-speciﬁ c solubility limits, 
stock concentrations of 2.5, 0.5, and 0.25 mM for BV and 
BRDT and of 0.75, 0.5 and 0.25 mM for the remaining 
TPs were tested in the TEAC, ORAC and FRAP assays. 
Results are presented in Figure 3A – C , and orders of eﬀ ec-
tiveness according to linear regression calculations are 
summarized in Table II . 
 The data (Figure 3A – C) attest to dose-dependent anti-
oxidant capacities for most of the tested compounds. Pro-
toporphyrin was highly eﬀ ective in the FRAP assay, and 
was moderately active in the ORAC and TEAC assays. In 
contrast, UB and SB were weakly and generally least 
eﬀ ective in all of the antioxidant capacity assays by show-
ing no reductive power in the FRAP assay against Fe 3   , 
a moderate activity in the ORAC and TEAC assay versus 
trolox. The remaining compounds (BR, BRDT, BV, BR-/
BV-DME) possessed moderate to high antioxidant activi-
ties in the various assay systems (Table II) . 
 Discussion 
 A series of novel (physiological) TPs were investigated in 
the  Salmonella reverse mutation assay and multiple anti-
oxidant capacity assays (TEAC, ORAC, FRAP) and were 
compared to already tested, biologically relevant BR and 
BV. In the absence of metabolic activation (-S9) the order 
of eﬀ ectiveness in the  Salmonella reverse mutation assay 
was PRO   BV   BRDT   BR   BV-DME   SB   
BR-DME   UB. In the presence of S9 the antimutagenic 
eﬀ ectiveness was reversed, suggesting UB   BV-DME   
BR-DME   SB   BV   BR   BRDT   PRO. These 
data imply that cytochrome P450 activity within the 
microsomal S9 mixtures probably oxidized PRO, BV and 
BR leaving only UB and SB to remain active (in the   S9 
condition). Furthermore, these data also indicate that 
methylation of BR ’ s and BV ’ s propionate groups protect 
them from cytochrome oxidation, allowing them to remain 
active, in the presence of metabolic activation. In the anti-
oxidant capacity assays most TPs possessed moderate to 
high antioxidant activities in comparison to trolox and 
Fe 2   . The only exceptions were UB and SB which pos-
sessed no FRAP ability, however, retained moderate 
ORAC and TEAC activity. These data are the ﬁ rst to indi-
cate that UB and SB act as antioxidants by donating 
hydrogen atoms to incumbent radical species. 
 It is evident that BR and BV are potent antioxidants  in 
vitro [21] as well as under  in vivo conditions [8 – 10]. They 
possess antimutagenic and antioxidant properties against 
multiple classes of mutagens in the  Salmonella reverse muta-
tion assay [6,7], both of which are generally attributed to 
electron/hydrogen donation and to free electron scavenging 
of peroxyl and superoxide radicals [12,21]. 
 To reveal possible mechanisms of antioxidant action of 
TPs, pigment solutions were tested in well-established assays 
to assess their direct (reducing) and indirect (oxidation 
preventative) antioxidant properties. The ORAC assay 
 tert- BOOH-induced DNA damage equally over the 
entire concentration range ( p  	  0.05) . However, no dose-
dependency was observed (Figure 2A) . 
 At all concentrations, BV-DME signiﬁ cantly lowered 
revertant formation ( p  	  0.05) , compared to positive 
control, and was generally more eﬀ ective than BV. How-
ever, also BV signiﬁ cantly lowered  tert- BOOH-induced 
oxidation at 0.1, 0.5, 1 and 2  μ mol/plate (Figure 2B) . 
 Bilirubin and BRDT exerted a nonsigniﬁ cant antioxi-
dant eﬀ ect at or below 0.1  μ mol/plate, and BR-DME sig-
niﬁ cantly lowered revertant formation at all doses compared 
to positive control counts ( p  	  0.05; Figure 2C) . 
 In the presence of S9, the calculated order of antioxi-
dant TP eﬀ ectiveness at 0.5  μ mol/plate was as follows 
(Table I) : UB   BV-DME   BR-DME   SB   BV   
BR   BRDT   PRO. 
 Figure 1. A – C The eﬀ ects of TPs (A) SB, UB, PRO, (B) BV, BV-DME 
and (C) BR, BRDT, BR-DME on  tert -BOOH-induced mutation in 
 TA102 . BR: unconjugated bilirubin, BRDT: bilirubin ditaurate, 
BR-DME: bilirubin dimethyl ester, BV: biliverdin, BV-DME: biliverdin 
dimethyl ester, UB: urobilin, SB: stercobilin, PRO: protoporphyrin. 
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assays, MacLean and colleagues showed an antioxidant 
behavior of both methylated compounds dependent upon 
free N-H groups for internal H-bonding, the nature of the 
solvent and on the attacking radical. Their hypothesized 
mechanisms of action included hydrogen atom transfer, 
proton-coupled electron transfer and single electron trans-
fer [21] and are supported by the ﬁ ndings presented here. 
 In the  Salmonella reverse mutation assay results, 
neither BR-DME nor BV-DME signiﬁ cantly protected 
against  tert- BOOH-induced oxidation in  TA102 (-S9) at 
the concentration range tested. However, in the presence 
of S9 both methyl esters exerted signiﬁ cant antigenotoxic 
eﬀ ects compared to positive control ( p  	  0.05; Table I). 
These divergent results indicate that cytochrome P450 
redox system-attributed structural modiﬁ cations of BPs 
are active possibly including de-esteriﬁ cation of the methyl 
esters and yielding unconjugated and bioactive compounds 
[33]. Correspondingly, if unconjugated pigments were 
added, we propose BP oxidation by cytochrome P450s, 
including rat CYP1A5, resulted in C10 bridge oxidation 
and formation of dipyrollic fragments as identiﬁ ed by 
DeMatteis et  al . [34]. Moreover, the speciﬁ c organic prop-
erties of dimethyl ester compounds have a great aﬃ  nity 
for lipid membranes, which might have altered their 
cellular distribution. In contrast, BRDT would remain 
in solution and unconjugated BR could be bound to 
lipids and proteins including albumin and glutathione-
S-transferases. 
 Although very little is known about the antioxidant 
properties of PRO, one report shows that it can eﬀ ec-
tively inhibit lipid peroxidation: when Williams et  al. 
tested PRO, lipid peroxidation was dose-dependently 
inhibited under light protection, suggesting antioxidant 
activity based upon peroxyl radical scavenging [23]. 
Another study reports that PRO is a potent antioxidant, 
(hydrogen atom transfer; HAT) speciﬁ cally detects the 
compounds ’ antioxidant capacity towards peroxyl radicals 
generated in the aqueous phase. The FRAP assay (single 
electron transfer; SET) exclusively measures the com-
pounds ’ iron reducing capacity, and TEAC detects the 
samples ’ antioxidant action towards the ABTS radical and 
combines both, the SET and HAT reaction types [32]. 
 Bilirubin and BV, together with BRDT proved most 
eﬀ ective in the TEAC assay (Figure 3A) , which suggests 
either electron donation or H-transfer as their underlying 
mechanism of action. Referring to the compounds ’ reduc-
ing capacity, Benzie and Strain found 1 mol of BR reduces 
4 mols Fe 3   in the FRAP assay [27]. In the present study 
however, 1  μ mol of BR was found to reduce 1.05  μ mol 
Fe 3   (Table II) . The observed decreased eﬀ ect and the 
generally changed orders of compound eﬀ ectiveness 
between the  in vitro systems might have been due to the 
albumin-free (and DMSO containing) conditions in the 
antioxidant capacity assays, versus protein containing 
bacteria. Binding of BR to albumin alters the antioxidant 
behavior of the compound, and causes a strained conforma-
tion that favors electron donation from the C10 methylene 
bridge [3]. 
 The presented results show diﬀ erences in the antioxi-
dant potential of the free acids (BR and BV) versus their 
methyl esteriﬁ ed counterparts. The two methylated conju-
gates were moderately to weakly active in all of the tests 
(TEAC, ORAC, FRAP; Table II). Both compounds possess 
eight double bonds (with BR ’ s containing two additional 
hydrogens that can be abstracted) and proved almost equally 
eﬀ ective in terms of their antioxidant action, although BR-
DME was clearly more eﬀ ective than BV-DME in the 
TEAC assay. These ﬁ ndings can probably be attributed to 
the reduced C10 bridge of BR, allowing hydrogen atom 
donation. Performing standardized kinetic antioxidant 
 Table I. The modulatory eﬀ ects of structurally related TPs on genotoxicity in  S. typhimurium strain  TA102 . 
 Strain  Mutagen [mol/plate]  S9  Test compound 
 IP 0.5 [pos control 
inhibition, %] # 
 IC 75 [inhibitory dose, 
 m mol/plate] °  His    pos 
 TA 102  tert- BOOH 0.75   10   6  – BR   20 1.15
BRDT   34 0.126
BR-DME   2 0.62
BV   35 0.15 1871    150
BV-DME  19 n/a ^  
UB   4 n/a ^  
SB   17 2.93
PRO   36 0.04
 TA 102  tert- BOOH 0.75   10   6  + BR   20 11.86  
BRDT   9 2.78
BR-DME   39 1.94
BV   22 0.28 1344    145
BV-DME   44 n/a ^  
UB   47 2.69
SB   38 n/a ^  
PRO   15 1.65
 BR, unconjugated bilirubin; BRDT, bilirubin ditaurate; BR-DME, bilirubin dimethyl ester; BV, biliverdin; BV-DME, biliverdin dimethyl ester; UB, urobilin; 
SB, stercobilin; PRO, protoporphyrin;  # IP 0.5 : percentage positive control inhibition at 0.5  μ mol TP plate concentration (highest common stock sample dose): 
 “  ” indicates  tert- BOOH attenuating eﬀ ect,  “  ” amplifying eﬀ ect; IP 0.5 was selected to assess the order of TP eﬀ ectiveness.  ° IC 75 : test compound concentration 
( μ mol/plate) needed to attenuate positive control eﬀ ects by 25% (inhibitory dose). His    pos : average positive controls revertant counts   SD.  ^  n/a indicates 
TPs were devoid of antioxidant activity and/or curve progressions were inappropriate which made IC 75 calculation impossible/uncertain. 
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however, when combined with metals such as cobalt or 
tin, PRO clearly acted, like heme, in a pro-oxidant man-
ner [35]. These data complement the evidence presented 
here that shows in the presence of iron and cytochrome 
activity PRO was pro-oxidant (or lost its antioxidant 
capacity), whereas it was a potent antioxidant in the 
absence of S9. Further supporting data indicate that PRO 
was a weakly to moderately active antioxidant in both 
TEAC and ORAC assays and was highly eﬀ ective in the 
FRAP assay (Table II) . This observation suggests clear 
electron donating capacity of PRO and mechanistically 
adds to the previously stated hypothesis of Williams  et 
 al., who attributed strong peroxyl radical scavenging 
properties to PRO [23]. Regarding its eﬀ ects in  Salmo-
nella , PRO was the most active of all compounds in 
the -S9 condition, however, it was the least active when 
metabolic activation was present (Table I) . The polarized 
order of eﬀ ectiveness is most likely explained by the pre-
viously discussed eﬀ ect of iron-rich liver homogenate 
application. Furthermore, with eleven double-bonds PRO 
carries the most extended conjugated double bond sys-
tem of all tested TPs, allowing it to donate the greatest 
number of electrons to incumbent radicals. Based on 
strong  π -interactions, its conjugated ring system which 
is susceptible to redox interactions ( e. g. with the heme 
protein cytochrome P450), provides powerful covalent 
and noncovalent binding capacities towards metals or 
biomolecules [36,37], supporting a role for the molecule 
in binding and docking with mutagens. The compound ’ s 
physic-chemical properties support the conclusion of its 
strong electron donating capacity/antioxidant activity 
observed in the aqueous systems of FRAP and the 
 Figure 3. A – C Antioxidant capacities of TPs in the (A) TEAC, (B) 
ORAC and (C) FRAP assay. BR: unconjugated bilirubin, BRDT: 
bilirubin ditaurate, BR-DME: bilirubin dimethyl ester, BV: 
biliverdin, BV-DME: biliverdin dimethyl ester, UB: urobilin, SB: 
stercobilin, PRO: protoporphyrin. 
 Figure 2. A – C The eﬀ ects of TPs (A) SB, UB, PRO, (B) BV, BV-DME 
and (C) BR, BRDT, BR-DME on  tert -BOOH-induced mutation (+ 
S9) in  TA102 . BR: unconjugated bilirubin, BRDT: bilirubin ditaurate, 
BR-DME: bilirubin dimethyl ester, BV: biliverdin, BV-DME: biliverdin 
dimethyl ester, UB: urobilin, SB: stercobilin, PRO: protoporphyrin. 
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 Salmonella reverse mutation assay. Liver homogenates 
by nature possess high concentrations of free and pro-
tein-bound iron that could participate in redox interac-
tions. Consequently PRO could be oxidized or could 
indeed chelate iron and revert to heme, which is a potent 
pro-oxidant, abolishing any antioxidant eﬀ ects. Proto-
porphyrin occurs in the intestinal tract and is excreted in 
the feces at a concentration of 0.2 – 14.3 nmol/g feces 
[38]. These data suggest that PRO within the intestine 
could prevent oxidative DNA damage and therefore pro-
mote enteral integrity and gut health by an antioxidant 
mechanism. 
 Literature reports on the antioxidant eﬀ ects of UB and 
SB are rare. Research in this ﬁ eld mostly deals with the 
compounds ’ derivatives ( e. g. urobilinogens, UBG). For 
UBG, Nakamura  et  al. reported a slightly superior radical 
scavenging activity compared to BR. Furthermore, the 
authors suggest UBG suppressed free-radical-induced 
lipid oxidation [20], which would consequently argue for 
a strong antioxidant eﬀ ect in the lipid phase. Therefore, it 
was hypothesized that UB would be active in the ORAC 
assay. Since UBG represents an oxidized form of UB, the 
antioxidant activity of the latter might be comparatively 
enhanced. However, results show that UB and SB gener-
ally were the least eﬀ ective of all test compounds 
(Table II), which also supports the overall outcome from 
 Salmonella trials, discussed below. Both compounds were 
entirely inactive in the FRAP assay with undetectable sig-
nals after blank subtraction. However, the compounds 
were weakly eﬀ ective in the TEAC and ORAC assays, as 
hypothesized above. Accordingly, their antioxidant action 
can be attributed to H transfer within the aqueous phase 
(also in  Salmonella ). This novel outcome also supports 
the aforementioned theory of Nakamura  et  al., which 
refers to a suppression of free radical-induced lipid 
oxidation by UBG. 
 In the  Salmonella test, UB signiﬁ cantly attenuated  tert-
 BOOH eﬀ ects over the entire range of concentrations, in 
the presence of metabolic activation. These eﬀ ects need 
to be considered relative to the remaining test compounds, 
most of which did not signiﬁ cantly attenuate  tert- BOOH 
eﬀ ects. Therefore UB and SB were eﬀ ective relative to 
the remaining TPs. In the absence of S9 addition, neither 
SB nor UB showed substantial antigenotoxic potential 
(Table I). With reference to their greatly reduced number 
of double bonds within their conjugated system UB and 
SB represent the most oxidized species tested. Previous 
studies demonstrate that electron donation from BR occurs 
via the N-H pyrrole ring [21]. The reductive capacity 
decreases, if conjugation within the ring is lost, as is the 
case in UB and SB. 
 In summary, the obtained results conﬁ rm a strong 
reductive power of PRO, which on its own, was most 
eﬀ ective in  Salmonella (-S9) and the FRAP assay, fol-
lowed by the rubinoid compounds (UB, BRDT, BR-DME). 
Upon introduction of S9, antioxidant eﬀ ectiveness was 
reversed with UB and SB being amongst the most eﬀ ec-
tive of all tested compounds, followed by the methyl 
esteriﬁ ed TPs, which are not known to be targets 
for cytochrome oxidation. The relative potency of UB 
and SB in preventing oxidative DNA mutation, in the 
presence of S9, provides very important information as 
to a novel chemo-preventative role for these compounds 
in the gastrointestinal and urinary tracts. 
 Table II. Summary of the test compounds’ orders of antioxidant eﬀ ectiveness in TEAC, FRAP and ORAC assays, 
according to linear regression slope calculations. 
 BR, unconjugated bilirubin; BRDT, bilirubin ditaurate; BR-DME, bilirubin dimethyl ester; BV, biliverdin; 
BV-DME, biliverdin dimethyl ester; UB, urobilin; SB, stercobilin; PRO, protoporphyrin;  # Trolox/Fe 2   
values below orders of eﬀ ectiveness were calculated per 1  μ mol compound;  ° “ Neg ” : after blank subtraction 
negative values were obtained (therefore compounds were classiﬁ ed as non-active and excluded from respective 
ﬁ gures). To classify test compound eﬀ ectiveness ( “ high ” ,  “ moderate ” ,  “ weak ” ), tertiles were calculated for 
each individual assay. 
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 Conclusion 
 This study ’ s ﬁ ndings show evidence of a strong antioxi-
dant behavior of the TPs BR, BV and BRDT in the 
 Salmonella reverse mutation assay, and present the ﬁ rst 
data on an antioxidant activity of BR-/BV-DME, UB, SB 
and PRO  in vitro. Stercobilin, UB and PRO all of which 
are found in the intestinal tract, showed  in vitro antioxi-
dant activity, which highlights their possible  in vivo 
importance in preventing oxidative stress within the gut. 
Although  Salmonella reverse mutation assay results can-
not be directly transferred to the  in vivo condition, the data 
provide preliminary evidence to suggest a possible physi-
ological role of structurally related, partially oxidized TPs, 
in preventing oxidative DNA damage within the gut. 
Therefore these compounds could be beneﬁ cial if admin-
istered enterally for therapeutic means [39]. 
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Bilirubin, the principal and biologically most relevant bile pigment was for long considered to 
be only a waste product of haem catabolism. However, recent data show its remarkable 
biological potential, including antioxidant and anti-mutagenic effects. It is now assumed that 
bile pigments and derivatives exert these effects in multimodal ways, which are likely mediated 
via structure-based mechanisms. Albeit, the major scientific focus so far has been directed 
towards the compounds’ antioxidant action, and specifications on mutagen/tetrapyrrole 
interactions are lacking. Therefore structurally related bile pigments and derivatives (bilirubin/-
ditaurate/-dimethyl ester, biliverdin/-dimethyl ester, urobilin, stercobilin and protoporphyrin) 
were tested for anti-genotoxicity in the Salmonella reverse mutation assay in strains TA98 and 
TA102, together with the synthetic mutagen and environmental pollutant 2,4,7-trinitro-9H-
fluoren-9-one (TNFone). Tetrapyrroles were applied at physiologically relevant concentrations 
of 0.01 – 2µmol/plate. To explore the physic-chemical background, molecular systems of 
chlorine e6 porphyrin, bilirubin and biliverdin with TNFone were assayed using circular 
dichroism techniques, which consistently revealed suprastoichiometric anti-mutagenic effects. 
Addition of TNFone to chlorine e6 porphyrin, bilirubin/albumin and biliverdin/albumin led to a 
substantial change in pigment spectral characteristics, providing evidence for tight 
tetrapyrrole/mutagen interactions. These results are reflected in the bacterial model, in which the 
majority of compounds significantly attenuated TNFone-induced mutagenesis. Protoporphyrin 
was the most anti-genotoxic pigment, followed by the rubinoid- (un-/conjugated 






Bile pigments (BPs) are tetrapyrrolic dicarboxylic acids which are endogenously formed within 
haem catabolism. Haem, to which protoporphyrin (PRO) is an intermediate prefix form, is 
degraded enzymatically involving haem oxygenase and NADPH/biliverdin reductase (BLVRA). 
Besides biliverdin (BV) synthesis, carbon monoxide and free iron are also generated. Biliverdin 
is reduced to bilirubin (BR) via BLVRA. Urobilin (UB) and stercobilin (SB) represent further 
biologically relevant degradation products of BR which are found mainly in the intestinal tract, 
and are formed by the microflora within the intestinal lumen. An overall estimate of 300mg of 
BPs is excreted on a daily basis via urine and faeces [Vitek and Ostrow 2009]. It is well 
established that BR and BV adopt chiral “ridge-tile” [Boiadjiev 1999; McDonagh and Lightner 
1985; McDonagh and Lightner 1994; Mugnoli et al. 1983] and helical “lock-washer” 
[Goncharova and Urbanova 2008] conformations, both of which are stabilized by intramolecular 
hydrogen bonds. The helical inversion equilibrium between the two enantiomeric M- and P 
forms [Boiadjiev 1999] is typical for these pigments in solution and causes the zero resultant 
optical activity of aqueous pigment solutions. However, in the presence of chiral agents, the 
molecules preferably form one of the diastereoisomers upon complexation with the chiral host 
[Harmatz and Blauer 1975; Lightner et al. 1986], and become optically active. This enables to 
follow the subtle structural changes using circular dichroism (CD) spectroscopy [Goncharova 
and Urbanova 2008; Goncharova and Urbanova 2009]. The vibrational variant of circular 
dichroism, vibrational circular dichroism (VCD), is a CD technique applied in vibrational 
spectra. It follows the vibrational transitions that are localized in a molecule and can therefore 
determine the variation in molecular structure caused by biologically important interaction 
[Urbanová 2009; Urbanová 2012].  
Antioxidant effects have been attributed to BR in vitro [Bulmer et al. 2007; Mölzer et al. 2012] 
as well as it has been found physiologically beneficial [Horsfall et al. 2011; Novotny and Vitek 
2003; Vitek et al. 2002; Vitek and Schwertner 2007]. Furthermore, growing evidence suggests 
that especially BR also acts in a strongly anti-mutagenic manner in vitro [Bulmer et al. 2008; 
Bulmer et al. 2007]. A great number of publications refer to the ability of BPs and derivatives to 
lessen the genotoxic effects of a range of mutagens other than pro-oxidants in the Salmonella 
reverse mutation assay (Arimoto et al, 1980; De Flora et al, 1994; Arimoto et al, 1995; Tang et 
al, 1997; Dorner et al, 1997). In that respect, BR, BRDT and BV have recently been found 
highly effective against 2,4,7-Trinitro-9H-fluoren-9-one (TNFone)-induced mutagenesis 
[Bulmer et al. 2007]. Observed anti-genotoxic effects were hypothesized to be due to physic-
chemical interactions, based on three-dimensional molecule structures [Bulmer et al. 2007]. 




systems (organs) where they could protect against different mechanisms of DNA damage 
induced by various (exogenous) noxae.  
To further explore our research hypothesis that TPs inhibit genotoxicity in a structure-dependent 
manner, the present study aimed to test the anti-genotoxic effects of a variety of yet untested 
compounds (BR-/BV-dimethyl ester, UB, SB, PRO) against TNFone in the Salmonella (S.) 
reverse mutation assay, applying bacterial strains TA98 and TA102. The fluorene derivative 
TNFone is a synthetic polycyclic nitroamine which was previously found in photocopier toners 
[Kari 1992]. It is a proven frameshift mutagen [Levin et al. 1979] and was uniformly found 
mutagenic in a series of genetic toxicity evaluations in S. typhimurium strains, with and without 
metabolic activation, as well as in animal trials [Kari 1992]. Since TNFone, its chemical 
structure and potential ways of interaction with molecules (e. g. DNA bases) have been studied 
well in the past, it represents an excellent model for testing structure-based anti-mutagenic 
effects. Tetrapyrrole/mutagen interactions in the sense of co-incubations however, have not 
been investigated so far, and therefore mechanistic data are entirely lacking. This information 
however is of high relevance since TNFone represents a common pollutant [Kari 1992] millions 
of people are exposed to on a daily basis. Furthermore, substantial biliary excretion was found 
in rats and mice after dermal and oral TNFone-administration [Kari 1992], which underlines the 
possible importance of a BP-based TNFone-detoxification in the hepato-biliary and 
gastrointestinal systems.  
Thus, we tested 1) whether a range of mostly untested BPs could modulate TNFone-induced 
genotoxicity and 2) how structurally related TPs affect mutagen genotoxicity by exploring 
possible structure-related mechanisms of action, using circular dichroism spectral studies 
 
2. Materials and Methods 
2.1. Salmonella reverse mutation assay:  
The S. reverse mutation assay is a screening method to assess the mutagenic potential of 
chemicals in vitro [Maron and Ames 1983]. Mutagenic substances revert mutated bacteria to 
their wild type variant which allows them to grow. Based on that, genotoxicity and anti-
genotoxic effects of compounds can be assessed by quantifying bacterial growth.  
 
2.2. Chemicals:  
Unconjugated bilirubin IXα (BR) [CAS# 635-65-4], bilirubin conjugate (ditaurate) disodium 
(BRDT) [CAS# 635-65-4], biliverdin IXα (BV) [CAS# 55482-27-4], bilirubin dimethyl ester 
(BR-DME) [CAS# 19792-68-8], biliverdin dimethyl ester (BV-DME) [B610-9; CAS# 10035-




77-6] as well as urobilin (UB) [CAS# 28925-89-5] and stercobilin (SB) [CAS# 34217-90-8] 
were purchased from Frontier Scientific, UK. Compound purity (> 98 %) was assessed using 
high pressure liquid chromatography (HPLC). All reagents and mutagens were obtained from 
Sigma Aldrich, Austria (unless otherwise noted), were of the highest analytical grade available 
and stored according to instructions until use. Sample solutions (prepared in DMSO) were 
protected from light using cling film and were used immediately. Composition and preparation 
of all necessary reagents and solutions can be found elsewhere [Bulmer et al. 2007].  
 
2.2.1. Positive/negative controls:  
The applied positive control was TNFone (Vitas-M Lab, Russia) dissolved in DMSO which also 
served as a negative control (Table I). 
 
 
Table I: TNFone was used as positive control. DMSO served as solvent and negative control.  
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2.2.2. Bacterial strains:  
S. typhimurium strains were kindly provided by Dr. Bruce N. Ames (University of California, 
Berkley, USA) and stored at -80°C as frozen permanents until use. Following [Mortelmans and 
Zeiger 2000], the strains were attested to their genetic integrity and spontaneous mutation rate. 
To consider different mechanisms of mutations two distinct strains were adopted: the DNA 
repair proficient strain TA102 detects A/T base pair damage and small deletions provoked by 
cross-linking agents and can be reverted by mutagens causing oxidative damage; strain TA98 
primarily detects G/C base pair and frameshift mutations [Mortelmans and Zeiger 2000].  
 
2.2.3. Sample preparation:  
Based on preceding investigations [Bulmer et al. 2007] and on a series of solubility 
experiments, six doses of BRDT, BV and newly tested BR-/BV-DME, UB, SB and PRO were 
assayed at concentrations of 0.01, 0.05, 0.1, 0.5, 1 and 2 µmol/plate. Bilirubin was tested up to 
0.75µmol/plate. Respective maximum compound concentrations had been ascertained by 1) 
testing the maximum amount of DMSO that did not lead to bacterial cytotoxicity (presence of 
background lawn on plates) and 2) by the respective maximum solubility of each compound 
(supernatant analysis: photometric and HPLC after high speed centrifugation). Bile pigment 
stock solutions were prepared at 0.025 M and dilutions containing the aforementioned amounts 
of TPs (in 300 µl) were made in DMSO. For both strains, DMSO toxicity was assessed by 
screening the background lawn present on minimal glucose agar plates after having added 
increasing amounts (0 - 500µl) of the diluent.  
 
2.2.4. Experimental design:  
The assays were performed in a dimly lit laboratory under sterile working conditions (Laminar 
airflow cabinet Safemate 1.8; Bioair Euroclone, Italy). Samples were protected from light 
throughout all experiments and were freshly prepared in amber vials before each test. For the 
experiments 500 µl of PBS buffer, 100 µl of overnight culture and 200 µl of TP solution (in 
DMSO) were merged in sterile test tubes. For anti-mutagenic testing 100 µl of mutagen (in 
DMSO or DMSO alone for controls) was added to each tube. After 25 mins of pre-incubation 
(37 °C, on rotary-shaker) 2 ml of molten top agar was added to every tube. The mixtures were 
poured onto minimum glucose plates, followed by 48 hrs of incubation at 37 °C. His+ 
phenotype revertants (colonies with reversion of mutations in the histidine operon are able to 
grow in the absence of histidine [Mortelmans and Zeiger 2000]) were counted manually after 
having routinely checked the background lawn under a microscope (40 x magnification; 




Each sample was tested in triplicate and all of the assays were repeated again on a different day. 
Every test included three “positive control plates” (mutagen only; n = 6), six “negative control 
plates” (no mutagen, no pigment; n = 6) and three “no treatment plates” (no mutagen, no 
pigment, no DMSO; n = 3). For a substance to be classified genotoxic in the S. reverse mutation 
assay, the number of revertant colonies on the compound plates had to exceed twice the number 
of colonies produced on the negative control plates [Mortelmans and Zeiger 2000].  
Besides investigating anti-mutagenic effects of TPs also spontaneous mutagenic effects were 
tested. For each sample, the respective highest and lowest concentrations were applied without 
mutagen addition.  
 
2.3. Characterization by circular dichroism 
The CD spectra of BPs were measured in a quartz cuvette with an optical path length of 1 cm 
(Starna, USA), using a J-810 spectropolarimeter (Jasco, Japan). The final spectrum was 
obtained as an average of three accumulations. Spectra were corrected for baseline by 
subtracting the spectra of the corresponding solvents. Circular dichroism measurements were 
conducted at room temperature (25 °C). For spectral measurements, BR, BV in the form of 
sodium salts, and chiral porphyrin CL in double distilled water were at concentrations of 1.2 x 
10-5 M. The sodium salts of the pigments were prepared by freeze-drying as described before 
[Goncharova and Urbanová 2007]. Human serum albumin (HSA) was used as a chiral 
discriminator for BR and BV at the pigment/HSA molar ration of 1/1. The chiral derivative of 
PRO (CL) was chosen to follow the interaction with TNFone utilizing CD in the absence of a 
chiral discriminator (chemical structures of compounds can be found in the online 
supplementary material 1). Vibrational CD spectra of CL with TNFone were recorded in 
DMSO d6/D2O (50:50) solution, at a concentration of 0.03 M with a resolution of 8 cm-1, using 
a Fourier transform infrared spectrometer IFS-66/S (Bruker, Germany), equipped with a 
VCD/IRRAS module PMA37 (Bruker). A demountable cell with CaF2 windows and Teflon 
spacer of a 50 µm pathlength was used. To interpret the VCD and IR spectra of CL with and 
without TNFone, a possible structure of the CL/TNFone complex was modelled (Fig. 3). 
Structure optimization was carried out by the HyperChem 8 software package [Hypercube 
2012], using the Amber 99 force field [Cornell et al. 1995].  
 
2.4. Statistical analyses:  
Values are presented as means ± SD. Parametric statistical analyses (ANOVA) and the post hoc 
Scheffé test were performed on normally distributed data, and corresponding non-parametric 




IBM SPSS 17.0 and Microsoft Excel 2007 for Windows. A p-value ≤ 0.05 was considered 
significant. To assess differences in revertant growth, data were analyzed using IP0.5 values 
(percentage of positive control inhibition at 0.5µmol of compound per plate) which assisted in 
standardising the orders of effectiveness in every test. A variety of curve algorithms were fitted 
to the data using Micrsoft Excel 2007 (linear, logarithmic, polynomial, exponential) and in 
every instance the algorithm with the highest R2 value was chosen [Bulmer et al. 2007]. IP0.5 
values were interpolated from these algorithms using Derive 6 (Texas Instruments) to determine 
the orders of TP effectiveness in the reverse mutation assay. 
 
3. Results  
3.1. Mutagenic testing in S. typhimurium strains TA98 and TA102 
Testing TPs for spontaneous mutagenesis revealed no pro-mutagenic effects in neither of the 
tested compounds and concentrations (p > 0.05; data not shown). 
 
3.2. Anti-mutagenic testing in S. typhimurium strain TA98 
Protoporphyrin attenuated TNFone-induced mutagenesis in a dose-dependent manner, and was 
the most effective of all tested TPs (p < 0.01) over the entire range of concentrations, in which 
the highest dose of 2 µmol/plate lowered TNFone effects by 90 % (Fig. 1A).  
Also BR and BRDT dose-dependently lowered TNFone-induced mutation. At all tested 
concentrations the compounds significantly inhibited mutagenesis (p < 0.05). Bilirubin 
dimethyl ester was significantly anti-mutagenic from 0.5 µmol/plate (p < 0.05; Fig. 1B).  
Compared to the rubinoid group of compounds, BV and BV-DME, were significantly active 
over a smaller range of concentrations (0.5 – 2 µmol/plate) compared to positive control (p < 
0.05, Fig. 1C). The overall effectiveness of BV was greater relative to BV-DME, but no dose-
dependency was found (Fig. 1C). In contrast, both UB and SB dose-dependently lowered 
TNFone-induced genotoxicity. Urobilin was significantly anti-mutagenic at all tested 
concentrations (except for 0.1 µmol), as was SB from 1 µmol/plate (p < 0.05, Fig. 1A). 
The order of effectiveness based on IP0.5 values was assumed as follows (Table II): PRO > BR 
> BR-DME > BRDT = BV-DME > UB > SB > BV. 
 
3.3. Antioxidant testing in S. typhimurium strain TA102 
As previously seen in strain TA98, PRO yielded the most pronounced anti-genotoxic effects of 
all tested compounds (p < 0.01), and attenuated TNFone by approximately 75 % at the highest 
tested concentration. Throughout all concentrations, it reduced TNFone-induced mutagenesis 




Also BR at the highest tested concentration of 0.75 µmol/plate significantly attenuated 
TNFone-induced mutagenesis (p < 0.01) in comparison to positive control, and a 
concentration-dependent effect was observed. As already seen in strain TA98, also in strain 
TA102 BR-DME dose-dependently inhibited TNFone effects (Fig. 2B).  
Both BV and BV-DME also significantly lowered TNFone-induced mutagenesis in TA102 in a 
dose-dependent manner (p < 0.05). Somewhat contrasting TA98 results, the overall anti-
mutagenic effects of BV-DME were comparably stronger within these two TPs (Fig. 2C).  
From a concentration of 0.1 µmol/plate also UB and SB significantly and dose-dependently 
inhibited TNFone-induced genotoxic effects (p < 0.05, Fig. 2A).  
The order of effectiveness based on IP0.5 values was assumed as follows (Table II): PRO > BR > 





Table II: The impact of different tetrapyrroles on genotoxicity in S. typhimurium strains TA98 
and TA102 
Strain Mutagen [mol/plate] Test compound IP0.5 [%]# His+pos° 




331 ± 22 
  BRDT -48 
  BR-DME -37 
  BV -37 
  BV-DME -26 
  UB -17 
  SB -17 
  PRO -90 




1157 ± 148 
  BRDT -53 
  BR-DME -54 
  BV -37 
  BV-DME -53 
  UB -50 
  SB -42 
  PRO -74 
 
BR: unconjugated bilirubin, BRDT: bilirubin ditaurate, BR-DME: bilirubin dimethyl ester, BV: 
biliverdin, BV-DME: biliverdin dimethyl ester, UB: urobilin, SB: stercobilin, PRO: protoporphyrin. 
#IP0.5: percentage positive control inhibition at 0.5 µmol TP per plate (highest common sample dose), “-“ 
indicates positive control attenuating, “+” enhancing effect; °His+pos: average positive controls revertant 






























Fig. 1A – C: Anti-mutagenic effects of A) PRO, UB, SB; B) BR, BRDT, BR-DME and C) BV, BV-DME 






























Fig. 2A – C: Anti-mutagenic effects of A) PRO, UB, SB; B) BR, BRDT, BR-DME and C) BV, BV-DME 






3.4. Circular dichroism characterization of pigment/mutagen interactions 
The influence of TNFone on CD spectra of the molecular systems composed of pigment and 
HSA in the case of BR and BV, and without HSA in the case of CL, is demonstrated in Fig. 3. 
Bilirubin and BV showed the typical absorption spectra observed in aqueous solutions and 
negligible CE signals, whilst a pronounced CE spectrum was observed for CL, which 
documented its high enantiomeric excess. Addition of HSA (to BR and BV) and TNFone 
resulted in the appearance of the signal at wavelengths of < 350 nm; the absorption signals in 
the blue (380 – 480 nm) and red regions (> 600 nm) are characteristic for pigments, whereas BR 
exerted a pronounced signal only in the blue region. Presence of HSA in BR and BV solutions 
induced a shift in absorption and strong CD signals as documented earlier [Goncharova and 
Urbanova 2008]. Chlorine, as a chiral compound without fast racemization in solution, per se 
showed a CD signal without the presence of a chiral agent. The variation of the CD signal 
intensity of the blue band was chosen as the quantitative parameter, describing the spectral 
changes upon TNFone addition. Addition of TNFone at the pigment/TNFone ratio of 1 caused 
66, 26 and 13 % variation of the blue band CD intensity for CL, BR and BV, respectively. The 
same spectral variation was observed at the pigment/TNFone ratio from 1 to 3, and about half 
that variation was observed for pigment/TNFone (= 0.5; data not shown). Evidently, TNFone 






Fig. 3: UV-vis absorption and CD spectra of BV, BR and CL in aqueous solutions (red lines), in the 
presence of HSA (blue line) and with TNFone (black lines). Concentration of all compounds was 
1.2 x 10-5 M. 
 
 
Figure 4 shows VCD and IR absorption spectra of CL with and without TNFone. Significant 
VCD spectral changes were observed in the presence of TNFone, which clearly indicated a 
diastereometric interaction between both compounds. The spectral observations are described in 
relation to a structure of the complex (Fig. 5) which was obtained by the energy minimization 
using the molecular mechanics. The VCD signals assigned to the symmetric and asymmetric 
COO- vibrations at 1590 – 1550 and 1440 – 1380 cm-1, respectively, were observed for CL 
without TNFone and were assigned to propionate in the 2(S)-propionic acid group (Fig. 4 and 5, 
position a). Addition of TNFone caused a significant increase in VCD signals at 1580 and 1562 
cm-1 localized in the region of asymmetric COO- vibrations which became strong, well resolved 
and of different shape than for CL alone. This can be explained by a chiral spatial fixation of the 
carboxylic groups in the CL part of the diastereometric complex. Besides the propionate, which 
is located in close proximity to the chiral center in the CL molecule, especially carboxymethyl 




Upon addition of TNFone, the IR absorption and the negative VCD signal at 1730 cm-1 was 
assigned to the C=O characteristic vibration localized in the flourenone (Fig. 4). In the 
suggested structure of the complex, the C=O position is appropriate for H-bondings shown in 
Fig. 4, position c. The signals at 1530 and 1340 cm-1 were assigned to the asymmetric and 
symmetric dinitro (NO2) vibrations, respectively, localized in the TNFone molecule (Fig. 4 and 
Fig. 5, positions d). A specifically strong VCD signal was observed for symmetric NO2 
vibration at 1340 cm-1 (Fig. 4), which indicated induced optical activity by possible π/π 
interaction between the nitro- (N) and dinitro-aromatic rings of TNFone with the CL pyrroles, 
as assigned in Fig. 5. The π/π interaction between the aromatic rings of the two partners in the 
complex was also confirmed by a strong induced negative VCD signal at 1610 cm-1, 
characteristic to C=C/C=N vibrations, which were observed upon addition of TNFone. The 
assignment of the VCD signals was confirmed by the spectra obtained for the half TNFone 

















Fig. 4: IR absorption and VCD spectra of CL in DMSO-d6/D2O (50:50) (green) and with TNFone for the 



















4. Discussion:  
Physiologically relevant concentrations of BR, BRDT, BR-DME, BV, BV-DME, UB, SB and 
PRO were tested in S. typhimurium strains TA98 and TA102 to assess their potential to 
modulate TNFone-induced mechanisms of genotoxicity. In both of the bacterial strains, cyclic 
PRO was the most effective of those compounds tested. Also linear BR, BRDT and the 
esterified compounds strain-independently showed high anti-mutagenic activities. Least active 
in both test conditions were structurally highly inter-related SB and UB.  
In a previous study [Bulmer et al. 2007] BR, BRDT and BV dose-dependently inhibited 
TNFone-induced mutagenesis. These strong anti-mutagenic effects for the above open-chain 
TPs are supported by our findings and can possibly be discussed with reference to their 
respective structural characteristics, bringing forward three-dimensional interactions. Both BR 
and TNFone carry ridge-tile conformation which according to the hypothesis forms the 
structural basis of their interaction [Bulmer et al. 2007]. Somewhat contrasting this hypothesis, 
also planar PRO exerted the most potent effects against TNFone-induced genotoxicity in both 
tester strains. Along with BR, also BR-DME shows a flexed out-of-plane conformation, 
supporting structural interaction with TNFone, as hypothesized. Urobilin and SB are as well 
non-planar in shape but do not possess specific flexed conformations, which is reflected in their 
weak anti-genotoxic activity, as is true for BV and its dimethyl ester derivative.  
To prove whether TNFone directly interacts with PRO, chiral CL was used as a model 
molecule. The variation in absorption induced by the presence of TNFone in CL solutions (Fig. 
3), were analogical to the previously described absorption spectra [Gladkova et al. 2010], 
caused by oxidations of CL. Our pronounced CD spectral changes induced by the addition of 
TNFone showed strong interactions between both compounds. The VCD results confirmed this 
interaction between CL and TNFone. The induced VCD signal in originally optically inactive 
TNFone observed in the presence of CL was localized in the region C=O and NO2. Upon the 
CL/TNFone interaction, the pronounced variation in the VCD signal was observed for the COO- 
vibrations localized in the CL molecule. The observed spectral changes are consistent with the 
suggested complex structure (Fig. 5). In Salmonella, PRO was most active against TNFone, 
followed by the rubin group of compounds. Comparing this order of effectiveness to CD results, 
strongly accentuates a direct compound/mutagen interaction, despite the compound’s planar 
shape. In both Salmonella strains PRO was clearly the most effective of all compounds tested, 
and strongly interacted with TNFone. Why planar PRO in contrast to other planar TPs is able to 
interact with TNFone remains uncertain. Reasons for its strong anti-mutagenic effects other than 
structural interactions could be its most substantial conjugated double bond system of all tested 




has the greatest binding capacity of all tested BPs due to strong π-interactions. This theory is 
also supported by the relatively weak anti-mutagenic effects of the least conjugated compounds 
UB and SB. Both compounds were equally active in both strains over the entire concentration 
range, which might have substantial implications for colon carcinogenesis, since these pigments 
are present at high concentrations within the intestinal lumen.  
The changes in CD intensity of the BR/HSA and BV/HSA adducts upon addition of TNFone, 
document interactions with it. The preserved position of the CD signal suggests minor variation 
of the chiral structure of the BR and BV part of the associates. This fact supported the idea that 
the spatial structure of pigments and TNFone fitted well and enabled the effective interactions, 
whereas BR acted as a more favorite partner for interactions than BV.  
 
In Salmonella BV was moderately to weakly anti-mutagenic in both tester strains, which can 
probably be attributed to its planar shape and comparably smaller π-electron system. Its anti-
mutagenic effectiveness was reflected by CD spectral changes, in which BV’s interaction with 
TNFone was the weakest of those compounds tested (PRO > BR > BV). Both BV and BV-DME 
are planar in shape which possibly explains the weaker protective potential against flexed 
TNFone, at least in strain TA102. Regarding their anti-mutagenic effects in both bacterial 
strains, both compounds were weaker than BR. The –COOH functional groups of BV carry two 
–CH3 groups to the C8 and C12 positions of the BV-DME molecule. In the TA98 condition BV 
was generally more effective than BV-DME. In TA102 the effects were inverted. In this 
experimental setting BV-DME was clearly more effective than BV. Therefore, it seems that 
aspects of functional supplementation influenced the compounds’ anti-mutagenic activities. 
As for BR, BRDT and BR-DME in both strains similar orders of compound effectiveness were 
obtained (BR > BR-DME > BRDT and BR > BRDT > BR-DME). Our results suggest that 
different functional groups attached to the carboxylic groups of the BR molecule do not seem to 
play crucial roles in anti-mutagenic action. In other words, free –COOH groups to C8 and C12 
of the BR molecule do not seem to be playing key roles in anti-mutagenesis. As previously 
mentioned, both BR (due to intramolecular hydrogen bonding) and BR-DME possess non-
planar structure, and can form BR’s preferred ridge-tile conformation [Bulmer et al. 2007; 
McDonagh et al. 2008] supporting a 3D-interaction. This hypothesis is supported by BR’s 
strong anti-mutagenic effects seen in both S. typhimurium strains.  
Due to similar anti-genotoxic activities of TPs observed between the different test models, a 
largely strain-independent anti-mutagenic mechanism can be assumed. Structure-based physic-




majority of TPs, and especially CD spectral changes observed for PRO, BR and BV confirm 
the compounds’ effectiveness against TNFone, and underline a direct structural interaction.  
 
5. Conclusion  
This study supports the hypothesis on a strong anti-genotoxic behavior of the tested 
tetrapyrrolic compounds. In that respect, our novel evidence supports existing data on an anti-
mutagenic activity of BR and BV and possible underlying physic-chemical events. Especially 
PRO continuously showed an enormous anti-mutagenic potential in our trials and strong 
PRO/TNFone structural interactions were newly revealed. Bilirubin was found to be the most 
effective among those compounds with known biological relevance. These data form the 
crucial basis for further interaction studies which might account for known potent biological 
effects of BPs.  
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In vitro anti-genotoxic properties of bile pigments have been explored and conﬁrmed recently. Despite
these reports mechanisms to explain DNA protection by endogenous bile pigments remain unclear. Sur-
prisingly, the quantiﬁcation of cellular pigment absorption which could represent a fundamental prere-
quisite for intracellular (e.g., anti-mutagenic) effects, has not been explored. Therefore, we aimed to
measure the amounts of un-/conjugated bilirubin as well as biliverdin absorbed into colonies of Salmo-
nella typhimurium, utilising HPLC analyses, and to observe whether intracellular compound concentra-
tions could predict anti-genotoxic effects. HPLC analyses conﬁrmed that bacterial bile pigment
absorption was concentration-dependent. Plate bile pigment concentrations were inversely associated
with genotoxicity of all tested mutagens, irrespective of strain and test conditions. However, protection
against frame-shift mutation in strain TA98 most strongly depended on the bacterial absorption of bili-
rubin and biliverdin, which indicates that bile pigments can protect by intercepting mutations extracel-
lularly and speciﬁcally inhibit frame-shift mutations intracellularly.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Bile pigments (BPs) such as bilirubin (BR) and biliverdin (BV)
are tetrapyrrolic, dicarboxylic compounds derived from the enzy-
matic heme degradation. They are distributed throughout the body
and thus could play an essential role in systemic and tissue-speciﬁc
health promotion. Numerous studies have identiﬁed anti-
mutagenic and anti-oxidative activity of speciﬁc tetrapyrroles
(TPs) in vitro (Asad et al., 2001; Bulmer et al., 2007). In vivo data
also demonstrate disease prevention through vasoprotection,
inhibition of inﬂammation and anti-oxidant activity (Bulmer
et al., 2008b; McCarty, 2007). Multiple underlying mechanisms of
anti-genotoxic action have been hypothesised but remain to be
conﬁrmed. Surprisingly, no publication has focused on quantifying
cellular BP absorption which could form a fundamental basis for
intracellular action. Therefore, we aimed to quantify the absorption
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, http://dx.doi.org/10.1016/j.tivstrains of Salmonella typhimurium (S. typhimurium) via HPLC analy-
ses. It was hypothesised that BPs would be absorbed in a dose-
dependent manner into bacteria, and that extracellular (plate)
and intracellular (absorbed) BP concentrations would broadly
protect against genotoxicity mediated by various mutagens.2. Materials and methods
2.1. Salmonella reverse mutation assay
The Salmonella reverse mutation assay is an in vitro test assess-
ing the mutagenic potential of chemicals. Bacterial wild-type
reversion in the presence of mutagens, allowing growth and colony
formation represents its fundamental, technical basis. Experiments
were conducted as previously published (Maron and Ames, 1983),
and included 48 h of BP incubation at 37 C. In some assays, S9 liver
homogenate (S9 microsomal fraction from Aroclor-treated rats)
was used as an enzymatic activation system. Bile pigment concen-
trations were tested in triplicate, negative/positive controls were
tested in each assay (n = 6). Experiments were repeated again on
a different day and results were then pooled (n = 6 minimum).
2.1.1. Bacterial strains
Two strains of S. typhimuriumwere tested: TA102, susceptible to
oxidative damage, reverts by cross-linking agents, TA98 detectslar anti-mutagenic effects of bile pigments in the Salmonella typhimurium
.2012.08.004
Table 1
Correlations between BP plate concentrations and bacterial pigment absorption in
Salmonella strains TA98 and TA102 (‘‘availability-based absorption’’).
Compound Strain Mutagen conc.
[mol/plate]
S9 Correlation (r)
BP absorption  BP plate
conc.
BR TA98 TNFone, 0.3  106  0.693**
BR TA102 TNFone, 0.2  107  0.972**
BR TA98 PhIP, 0.1  107 + 0.687**
BR TA98 AfB1, 0.8  107 + 0.982**
BR TA102 t-BOOH, 0.75  106  0.691**
BV TA98 PhIP, 0.1  107 + 0.949**
BV TA98 AfB1, 0.8  107 + 0.972**
BV TA102 AfB1, 0.24  106 + 0.949**
BV TA102 t-BOOH, 0.75  106  0.949**
BV TA102 t-BOOH, 0.75  106 + 0.949**
BRDT TA98 PhIP, 0.1  107 + 0.885**
BRDT TA102 AfB1, 0.24  106 + 0.972**
BRDT TA102 t-BOOH, 0.75  106  0.878*
BRDT TA102 t-BOOH, 0.75  106 + 0.814**
S9: metabolic activation system (microsomal fraction from Aroclor-treated rats);
BP: bile pigment; BR: unconjugated bilirubin; BV: biliverdin; BRDT: bilirubin
ditaurate; TNFone: 2,4,7-trinitro-9H-ﬂuoren-9-one; PhIP: 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine; AfB1: aﬂatoxin B1; t-BOOH: tertiary butyl
hydroperoxide.
** Signiﬁcant on p 6 0.01.
* Signiﬁcant on p 6 0.05.
2 C. Mölzer et al. / Toxicology in Vitro xxx (2012) xxx–xxxframe-shift mutations and base-pair deletions (Mortelmans and
Zeiger, 2000). Strains were kindly provided by Dr. Bruce N. Ames
and were attested to their genetic integrity and spontaneous
mutation rate (Mortelmans and Zeiger, 2000) in our laboratory.2.1.2. Chemicals
Unconjugated bilirubin 1Xa (CAS# 635-65-4), conjugated bili-
rubin (ditaurate; CAS# 635-65-4) and biliverdin 1Xa (CAS#
55482-27-4) were purchased from Frontier Scientiﬁc Europe, UK.
Chemical structures can be found online (Supplementary material
1). Pigment purity (>98%) and solubility were measured using
HPLC and spectrophotometry. The S9 liver homogenate was ob-
tained from MP Biomedicals, France. All other reagents and muta-
gens were purchased from Sigma Aldrich, Austria (unless
otherwise noted), were of the highest analytical grade available,
and stored according to instructions. Bile pigment solutions were
prepared in DMSO, protected from light, and used immediately.
Composition and preparation of all necessary solutions can be
found elsewhere (Bulmer et al., 2007). To assess different possibil-
ities of anti-genotoxic action (e.g., structural interactions, radical
scavenging, complex formation), four different mutagens wereTable 2
Correlations between BP plate concentrations or bacterial BP absorption, respectively, and
mutagenic effects’’ and ‘‘absorption-based anti-mutagenic effects’’).
Compound Strain Mutagen conc. [mol/plate] S9 Correlation (r) BP pla
BR TA98 TNFone, 0.3  106  0.794**
BR TA102 TNFone, 0.2  107  0.682**
BV TA102 TNFone, 0.2  107  0.493**
BV TA98 PhIP, 0.1  107 + 0.927**
BV TA98 AfB1, 0.8  107 + 0.473**
BV TA102 AfB1, 0.24  106 + 0.601**
BV TA102 t-BOOH, 0.75  106  0.607**
BRDT TA98 TNFone, 0.3  106  0.475**
BRDT TA102 TNFone, 0.2  107  0.378*
BRDT TA98 AfB1, 0.8  107 + 0.548**
BRDT TA102 t-BOOH, 0.75  106  0.754**
S9: metabolic activation system (microsomal fraction from Aroclor-treated rats); BP: b
TNFone: 2,4,7-trinitro-9H-ﬂuoren-9-one; PhIP: 2-amino-1-methyl-6-phenylimidazo[4,5-
** Signiﬁcant on p 6 0.01.
* Signiﬁcant on p 6 0.05.
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2,4,7-trinitro-9H-ﬂuoren-9-one (J & K Ltd., China; TNFone), ter-
tiary-butyl hydroperoxide (Merck; t-BOOH), aﬂatoxin B1 (AfB1)
and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (Toronto
Research Chemicals, Canada; PhIP).
2.1.3. Bile pigment sample preparation for the Salmonella reverse
mutation assay
Based on preceding investigations (Bulmer et al., 2007), BRDT
and BV were tested at concentrations of 0.01, 0.05, 0.1, 0.5, 1 and
2 lmol/plate (equals 3.4, 17.2, 34.5, 172.4, 349 and 689.6 lM).
Unconjugated BR was tested over a range of ﬁve doses including:
0.01, 0.05, 0.1, 0.5 and 0.75 lmol/plate (equals 258.6 lM). Maxi-
mum BP plate concentrations had been ascertained by (1) testing
themaximumamount of DMSO that did not result in bacterial cyto-
toxicity (200 ll/plate) and (2) by the respectivemaximumsolubility
of each test compound (spectrophotometric supernatant analysis:
BR, BRDT: 455 nm; BV: 380 nm), read on a Perkin Elmer Lambda 2
UV/VIS spectrophotometer after high-speed centrifugation.
2.2. Sample preparation for HPLC analyses
Brieﬂy, S. typhimurium colonies (P1 mm in diameter) were
collected from agar plates, and were lysed for 30 min in 40 ll of
isocratic mobile phase (950 ml HPLC-grade methanol, 50 ml
HPLC-grade water, 24.2 g n-dioctylamine and 6.01 g glacial acetic
acid per litre). Supernatants were diluted at 1:4, and injected
(50 ll) into a Hitachi HPLC, equipped with a Shimadzu SPD-
M20A detector, and a C18 reverse phase column (5micron,
250  4.6 m) (Brower et al., 2001; Bulmer et al., 2008b). Oven tem-
perature was set at 35 C, column pressure at 140 bar. Sixteen BP
standards were run, ranging from 500 to 0.01 lM. The method’s
detection limit (LOD) was calculated at 18 nM. Photographs of bac-
terial colonies can be found online (Supplementary material 2).
2.3. Measurement of total protein content
As a reference parameter for bacterial BP absorption, the total
protein content in each diluted sample was measured photometri-
cally (Bradford, 1976). Bile pigment concentrations were then ex-
pressed as nmol/mg total protein.
2.4. Statistical analyses
Data were analysed using SPSS 17.0. A p-value 60.05 was con-
sidered signiﬁcant. Data were tested for normal distribution usinganti-mutagenic effects in Salmonella strains TA98 and TA102 (‘‘availability-based anti-












ile pigment; BR: unconjugated bilirubin; BV: biliverdin; BRDT: bilirubin ditaurate;
b]pyridine; AfB1: aﬂatoxin B1; t-BOOH: tertiary butyl hydroperoxide.
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C. Mölzer et al. / Toxicology in Vitro xxx (2012) xxx–xxx 3the Kolmogorov–Smirnov test. Parametric statistical analysis
(one-way ANOVA) and the post hoc Scheffé test were performed
on normally distributed, and corresponding non-parametric tests
(Kruskal–Wallis H-test, Dunn’s post hoc test) on skewed data.Fig. 1. (A–C) Relationship between bacterial BP absorption and observed anti-mutagen
strain TA102 with TNFone, (C) BV in strain TA98 with PhIP and with S9.
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effects; and (3) between BP plate concentrations and anti-
mutagenicity were determined by performing bivariateic effects against different mutagens; (A) BR in strain TA98 with TNFone, (B) BR in
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parametric data, respectively).
3. Results
HPLC analyses showed signiﬁcant concentration-dependent BP
absorption from agar plates, which was independent of strain, test
condition (± S9) and the applied mutagen (Table 1). Furthermore,
anti-mutagenic effects of all BPs against all tested mutagens were
observed (Table 2).
The relationships between BP plate concentrations, bacterial BP
absorption and observed anti-mutagenic effects are shown in
Fig. 1A–C and in Supplementary material 3. Signiﬁcant inverse
relationships were found between BR plate concentrations in
strains TA98 and TA102 and anti-mutagenic action against TNFone,
as well as between BV plate concentration and PhIP mutagenesis in
TA98 (Fig. 1A–C). A typical chromatogram showing BR absorption
into strain TA98 is shown in Fig. 2. Furthermore, signiﬁcant corre-
lations between pigment plate concentrations and anti-genotoxi-
city were found for all test conditions (Table 2), indicating a
stronger concentration-dependent anti-mutagenic effect based on
extracellular (vs. intracellular) BP concentration. Interestingly,
the anti-mutagenic effects of BR and BV were most strongly depen-
dent on the bacterial BP absorption exclusively in strain TA98
(Table 2).
An entirely novel observation was also made in that the ob-
tained HPLC spectra (not shown) suggest appearance of BR in plates
supplemented with BV, which could imply biliverdin reductase
activity in S. typhimurium. The ratio of BV to BR (BV:BR) bacterial
concentrations calculated from HPLC chromatograms (at 1 lmol/
plate BV) approximated 4.4:1 in TA98 and 9.6:1 in TA102.
4. Discussion
This study is the ﬁrst to report on bacterial BP absorption and its
relationship with observed anti-mutagenic effects. When exposed
to mutagens, extracellular (plate) BP concentrations negatively
correlated with genotoxicity. Furthermore, testing in TA98 revealed
that BV and BR absorption was more strongly related with anti-
mutagenesis, when compared to the anti-mutagenic effect relative
to plate concentrations.Fig. 2. Chromatogram of BR (with TNFone) in Salmonella TA98 colonies.
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reverse mutation assay. Toxicol. in Vitro (2012), http://dx.doi.org/10.1016/j.tivPrevious reports refer to the ability of BPs to act in an anti-oxi-
dant and anti-genotoxic manner in vitro (Asad et al., 2001; Bulmer
et al., 2007) and in vivo (Boon et al., 2012; Horsfall et al., 2011).
Vastly unclear to date however, are the underlying mechanisms
of anti-genoxic action. In this context mainly electron scavenging
or hydrogen donating capacities (MacLean et al., 2008) and struc-
tural interactions between BPs and mutagens (Hayatsu, 1995) are
discussed. However, data on cellular compound absorption are
lacking and so far only one recent report on enzymatic BRDT reduc-
tion in bacteria (Konickova et al., 2012) exists. Therefore, we ex-
plored whether bacterial BP absorption was more closely related
to anti-mutagenesis compared to extracellular BP concentrations
around S. typhimurium experiencing genotoxic stress.
In this study, physiologically relevant concentrations of BPs
were tested. Un-/conjugated BR is found in the blood, the liver,
the intestine (where about 70% are recycled via the enterohepatic
cycle), and the urinary tract. In these compartments BR is further
metabolised, recycled and/or excreted (Klatskin, 1961). The liver
and gut, which are sites of BP accumulation, are at particular risk
of genotoxicity due to the absorption, metabolism (Guengerich,
2000; Turesky et al., 2002) and excretion of mutagens. The
abundance of BPs within these organs suggests BPs could exert
physiological protection against DNA damage speciﬁcally at these
sites.
Interestingly, BR and BV absorption strongly protected against
frame-shift mutation in the TA98 strain. This mutation represents
an important mechanism of pathogenesis in gastric and colorectal
cancers (Kim et al., 2010). We speculate that the afﬁnity of BPs to
protect against frame-shift mutation, might partly explain the pro-
tective relationship between serum BR levels and colorectal cancer
in vivo (Zucker et al., 2004). It should be emphasised, however, that
BPs do protect against oxidative and frame-shift mutation when
present extracellularly, indicating a clear role for BPs in neutralis-
ing mutagens before entering cells. Furthermore, it should be
noted that BR causes apoptosis in cancer cells in vitro (Keshavan
et al., 2004), providing an additional mechanism for chemopreven-
tion. These data further emphasise the importance of therapeuti-
cally elevating BR concentrations for the prevention of
cardiovascular disease and cancer (McCarty, 2007). Reports to indi-
cate that BV and BRDT are readily absorbed across cultured entero-
cytes (Bulmer et al., 2008a) support this theory. These data conﬁrm
that potential anti-mutagenic BP effects in vivo could be induced
by increasing concentrations in the gut lumen (Bulmer et al.,
2011) where food-borne mutagens are found, or by increasing
blood BP content in vivo to impart protection from DNA damage
(Wallner et al., 2012). Although the results of these in vitro exper-
iments cannot be directly extrapolated to in vivo settings, the re-
sults suggest BPs in the extracellular milieu (e.g., in the gut
lumen/blood) could play a key role in cellular protection, by inter-
cepting mutagens before they arrive at their site of action (e.g.,
DNA).Conﬂict of interest statement
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Epidemiological studies report a negative association between circulating bilirubin 
concentrations and the risk for cancer and cardiovascular disease. Structurally related 
tetrapyrroles also possess in vitro anti-genotoxic activity and may prevent mutation prior to 
malignancy. Furthermore, few data suggest tetrapyrroles exert anti-carcinogenic effects via 
induction of cell cycle arrest and apoptosis. To further investigate whether tetrapyrroles provoke 
DNA-damage in human cancer cells, they were tested in the single cell gel electrophoresis assay 
(SCGE). Eight tetrapyrroles (unconjugated bilirubin, bilirubin ditaurate, biliverdin, biliverdin-
/bilirubin dimethyl ester, urobilin, stercobilin and protoporphyrin) were added to cultured Caco2 
and HepG2 cells and their effects on comet formation (% tail DNA) were assessed. Flow 
cytometric assessment (apoptosis/necrosis, cell cycle, intracellular radical species generation) 
assisted in revealing underlying mechanisms of intracellular action. Cells were incubated with 
tetrapyrroles at concentrations of 0.5, 5 and 17 µM for 24 hrs. Addition of 300 µM tertiary butyl 
hydroperoxide to cells served as a positive control. Tetrapyrrole incubation mostly resulted in 
increased DNA-damage (comet formation) in Caco2 and HepG2 cells. Tetrapyrroles that are 
concentrated within the intestine, including protoporphyrin, urobilin and stercobilin, led to 
significant comet formation in both cell lines, implicating the compounds in inducing DNA-





1. Introduction:  
Bile pigments (BPs) such as bilirubin (BR), biliverdin (BV) and structurally related 
tetrapyrroles (TPs) are formed naturally within the human body. Derived from heme within 
hemoglobin and heme-containing enzymes, endogenous TPs possess porphyrin structure and 
carry a conjugated system of double-bonds [1]. Heme catabolism requires the action of heme 
oxygenase (HMOX-1/-2) and biliverdin reductase (BLVRA), within certain organs including 
the liver and intestine. Tetrapyrroles derived from this process are found in the bile (mainly 
conjugated BR), and in the intestinal milieu (mainly stercobilin SB, urobilin UB and 
protoporphyrin PRO) [2, 3]. The literature reports anti-mutagenic, antioxidant as well 
potentially anti-carcinogenic activity of BR and BV in vitro [4-8]. Further studies suggest an 
important role for mildly elevated circulating BR in preventing disease in human subjects [9-13] 
by antioxidant mechanisms [9, 11-13], and emphasize a protective physiological role for  
unconjugated BR in protecting against gastrointestinal and colorectal cancer [14]. These effects 
might also be related to BR’s intestinal abundance [14], with recent evidence indicating the 
potential efficacy of intestinal absorption [15, 16]. Consequently, physiologically abundant TPs 
could play significant health promoting roles in the organs where they are absorbed/accumulate 
including the liver, gall bladder and intestine in addition to the urinary tract and the circulatory 
system [16].  
Thus far, the scientific focus has mainly been directed towards in vitro anti-genotoxic properties 
of BR and BV [5, 17], with little attention focused on structurally related metabolites. 
Unconjugated BR induces cell cycle arrest, apoptosis and cytostasis in vitro in multiple cell 
lines [18]. Besides, BR may be defending against cancer by interfering with pro-carcinogenic 
signaling pathways, and therefore potently inhibit tumor cell proliferation in vivo [18]. 
Furthermore, BR induces mitochondrial depolarization in colon cancer cells [19]. However, data 
concerning the effects of related tetrapyrrolic compounds on cancer cell biology are entirely 
lacking, with the only exception being PRO which is successfully applied in the clinic [20]. 
Despite the use of PRO and derivatives in the photodynamic treatment of skin cancer [21, 22], 
in vitro comet data and evidence on pro-apoptotic, anti-carcinogenic and anti-proliferative 
effects of PRO in different cell culture models are rare [22-26]. Also the DNA-damaging effects 
of BR in cancer cells have been investigated only once [27], when applying the single cell gel 
electrophoresis (SCGE/comet) assay.  
Stress stimuli such as DNA-damage provoke cellular responses including oxidative stress, cell 
cycle arrest and apoptosis, the latter of which is mainly controlled by the action of tumor 




as well as alkylating agents induce DNA-damage within rapidly proliferating cells in an attempt 
to selectively target malignant cells. To assess whether TPs exert comparable effects on cancer 
cell lines (e. g. induce free radical formation), five essentially untested TPs (BR-/BV dimethyl 
ester (BR-/BV-DME), UB, SB, PRO) were investigated together with BR, BRDT and BV in 
human colorectal adenocarcinoma (Caco2) and hepatocellular carcinoma (HepG2) cells. These 
cell lines represent meaningful models for TP in vitro testing, since both the liver and intestine 
represent central organs for BP metabolism [29]. To elucidate cellular regulatory mechanisms in 
response to TP exposure, flow cytometry analyses (apoptosis/necrosis, intracellular radical 
species (ROS), cell cycle) were conducted to reveal underlying mechanisms of TPs action, 
relevant to cancer cell biology [21, 22, 26, 28, 30], while the comet assay was applied to 
determine the extent of DNA damage. 
 
2. Materials and methods:  
2.1. Chemicals 
Unconjugated bilirubin IXα (BR) [CAS# 635-65-4], bilirubin conjugate (ditaurate; disodium; 
BRDT) [CAS# 635-65-4], biliverdin IXα (BV) [CAS# 55482-27-4], bilirubin dimethyl ester 
(BR-DME) [CAS# 19792-68-8], biliverdin dimethyl ester (BV-DME) [CAS# 10035-62-8], 
protoporphyrin IX (PRO) [CAS# 553-12-8] as well as urobilin (UB) [CAS# 28925-89-5] and 
stercobilin (SB) [CAS# 34217-90-8] were purchased from Frontier Scientific, UK, and were 
dissolved in DMSO. Solubility was tested spectrophotometrically and (purity) via HPLC [15, 
31]. DMSO final concentrations in media did not exceed 0.1 %. Test compounds were stored in 
airtight and lightproof containers at -80 °C until use, and were protected from light throughout 
all test procedures using foil-covered containers. Other chemicals were purchased from Sigma 
Aldrich, Austria (unless otherwise noted), were of the highest analytical grade available and 
were stored and used according to instructions.  
 
2.2. Single cell electrophoresis assay  
The comet assay measures DNA single- and double strand breaks in eukaryotic cells embedded 
in 1 % low melting agarose (LMA; Invitrogen Austria), fixed on agarose pre-coated microscope 
slides (1 % normal melting agarose, NMA; Invitrogen Austria). After cell lysis at pH 10 and 20 
min of DNA unwinding (as well as 300 µM tertiary-butyl hydroperoxide (tert-BOOH) 
treatment for positive controls), cells were exposed to a directed electric field (Electrophoresis 




gel), DNA migration/comet formation was evaluated using a fluorescent microscope (Zeiss 
Germany) equipped with a camera (Hitachi Austria). Komet 5.5. software (Andor Technology, 
Germany) assessed comet tail DNA content which was expressed as a percentage of total 
cellular DNA (% tail DNA). The method of Azqueta et al. [32] was used to measure both DNA 
single- and double strand breaks. Human lymphocytes were replaced by cancer cells, using 1 x 
106 cells per ml. Eight gels (two per slide; per compound and concentration) were prepared for 
statistical and quality assurance analysis, six gels of which at minimum were randomly counted 
(50 cells/gel).  
 
2.2.1. Human cancer cell lines  
Cytotoxicity was assessed in two cell lines (Caco2 and HepG2) that were originally derived 
from primary human tumors as reported by the provider (source as below). Cell viability and 
cell counts were assessed using a trypan blue assay-based automated cell counter (Countess; 
Invitrogen, Austria).  
 
2.2.1.1. Cell culture media  
Cells were obtained from the German Collection of Microorganisms and Cell Cultures (Leibniz 
Institute, DSMZ), and were maintained using standard culture techniques. Caco2 cells were 
cultivated in antibiotic-free Dulbecco’s modified essential medium (DMEM with high glucose; 
PAA Austria), and HepG2 cells in Eagle’s minimum essential medium with Earle’s salts 
(MEM; PAA Austria) in sterile 25 cm2 filter cap flasks (SPL Life Sciences Inc., Austria). Media 
were supplemented with 10 % (v/v) fetal bovine serum (FBS; PAA Austria), 5ml of non-
essential amino acids, 1 ml of Na-pyruvate (HepG2) or 20 % FBS (v/v) and 1 ml of 100 mM 
Na-pyruvate (Caco2). Experiments were conducted between passages 17 – 37 for Caco2, and 34 
– 54 for HepG2 cells. Media were changed every second day and on the day before and after 
cell splitting, which was performed at 70 – 80 % confluence, using 1 ml per flask of Accutase 
solution (PAA Austria). For TP incubation, 4.5 x 105 cells/ml were seeded in sterile 24 well 
plates (SPL Life Sciences Inc., Austria) and were allowed to adhere for 24 hrs. All cultures were 







2.3. Flow cytometric analyses  
After 24 hrs of TP incubation, cells were harvested from 24 well plates and transferred to 5 ml 
FACS tubes (BD Biosciences, Austria). After treatment including centrifugation, washing and 
staining steps, cell suspensions were analyzed using a BD FACSCalibur flow cytometer (BD 
Biosciences, Austria).  
 
2.3.1. Apoptosis/Necrosis assay  
The applied detection kit (r-phycoerythrin (PE) annexinV apoptosis detection kit I, BD 
Pharmingen Austria) was used to measure apoptosis and necrosis via flow cytometry. This 
assay requires the Ca2+-dependent affinity of annexinV to phosphatidyl serine as well as the 
specificity of 7-aminoactinomycin-d (7-AAD) for guanine-cytosine DNA-base pairs for the 
assessment of apoptosis and necrosis. Briefly, 1 x 106 cells/ml were washed in Ca2+/Mg2+-free 1 
x phosphate buffered saline (PBS; PAA Austria) and re-suspended in binding buffer, were 
doubly labelled with PE-stained annexinV (exmax: 496, emmax: 575 nm; FL-2), and 7-AAD 
(exmax: 546, emmax: 647 nm; FL-3) and were incubated for 15 min in the dark prior to cytometric 
analyses [33, 34].  
 
2.3.2. Intracellular radical species  
To detect intracellular reactive oxygen species (ROS), 10 µM final concentration 
dihydroethidium (DHE) and 25 µM final concentration dihydrofluorescein diacetate (DCFH-
DA), both in DMSO, were added indivdually to incubated cells. Dihydroethidium is cell-
permeable and reacts with O2-. to form oxyethidium. This product interacts with nucleic acids 
and emits red fluorescence, which can be measured cytometrically (exmax: 329, emmax: 373 nm; 
FL-2) [35]. When DCFH-DA enters the cell, it is cleaved by intracellular esterases to form 
DCFH, which is then non-specifically oxidized by (hydro)peroxides to fluorescent 7'-
dichlorodihydrofluorescein (DCF) (exmax: 498, emmax: 522 nm; FL-1) [35]. After washing in 
Ca2+/Mg2+-free 1 x PBS and prior to measurement, 1 x 106 cells/ml were stained with DHE (in 
FACS tubes after harvesting) or with DCFH (in 24 wells prior to harvesting) and were left to 







2.3.2. Cell cycle assay  
The cell cycle assay measures the percentage number of cells in the cell cycle phases G0/1, S, 
G2/M, as well as apoptotic cells (sub G0/1), according to fluorescence intensity, based on the 
number of DNA copies within cells. Propidium iodide (PI; exmax: 535, emmax: 617 nm; FL-2) 
binds to DNA by intercalating between the bases with a stoichiometry of one PI molecule per 
4.5 DNA base pairs. After washing, 1 x 106 cells/ml were fixed with 75 % ice-cold absolute 
ethanol and were left to incubate for 30 min on ice. Cells were re-suspended in 500 µl of 
phosphate buffer (96 ml 0.2 M Na2HPO4 + 4 ml 0.1 M C6H8O7), and after centrifugation, 50 µM 
of 100 µg/ml RNase and 200 µl of 50 µg/ml PI (both in dH2O) were added [37, 38]. Cell 
suspensions were measured immediately.  
 
2.4. Statistical analyses  
To evaluate DNA-damaging effects of TPs in the comet assay, 50 cells per gel were counted. As 
a measure of DNA-damage, mean percentages of total DNA (% tail DNA) were calculated in 
Microsoft Excel. Statistical analysis was completed using IBM SPSS 19 for Windows. Normal 
distribution of the data was assessed using the K-S test. To calculate differences in DNA-
damage between groups, ANOVA was performed on parametric data and Kruskal-Wallis H-test 
on non-parametric data, followed by the Dunnet-T3 post-hoc test, assuming non-homogenous 
variances. Pearson bivariate correlations were performed on parametric, Spearman rho on non-
parametric data. A p-value ≤ 0.05 was considered significant.  
 
3. Results:  
3.1. DNA-damage/comet formation in Caco2 and HepG2 cell lines:  
3.1.1. Protoporphyrin, urobilin, stercobilin 
In both cell lines, PRO at the highest and lowest tested concentrations induced significant DNA-
damage versus negative control (p < 0.05), as was the case in HepG2 cells, also in comparison 
to positive control (p < 0.05; Figures 1A and 2A). Following UB incubation in both cell lines, 
DNA-damaging effects tended to be or were significantly increased compared to negative 
control (p < 0.05; Figures 1B and 2B). In HepG2 cells, SB elevated DNA-damage compared to 
negative and positive control (p < 0.05; Figure 2C).  
3.1.2. Bilirubin, bilirubin ditaurate, bilirubin dimethyl ester 
In Caco2 cells, the highest tested BR concentration led to significantly reduced comet formation 




0.5 µM showed significantly elevated DNA-damage versus negative control in Caco2 cells (p < 
0.05; Table 1). In HepG2 cells however, BRDT did not induce DNA-damage compared to 
negative or positive control (p < 0.05; Table 1). Bilirubin dimethyl ester incubation with Caco2 
and HepG2 cells showed no DNA-damaging effects.  
3.1.3. Biliverdin, biliverdin dimethyl ester 
In Caco2 cells, BV and BV-DME did not significantly increase DNA-damage versus negative 
control (p < 0.05; Table 1). However, BV incubation in HepG2 cells caused significantly 
elevated DNA-damage at all tested concentrations compared to the negative control (p < 0.05; 
Table 1). Also BV-DME at the lowest and highest tested concentration led to significantly 
elevated DNA-damage compared to negative control (p < 0.05; Table 1). 
 
3.2. Correlations between DNA-damage/comet formation and flow cytometry 
parameters: 
3.2.1. Protoporphyrin, urobilin, stercobilin 
In HepG2 cells, a positive relationship between PRO-induced comet formation and intracellular 
ROS (superoxide) production was determined (p < 0.05; Table 2). Superoxide formation after 
PRO incubation in HepG2 cells was positively correlated to apoptosis (r 0.529, p < 0.05). 
3.2.2. Bilirubin, bilirubin ditaurate, bilirubin dimethyl ester 
For BR, a positive correlation was determined between comet- and intracellular ROS formation 
(superoxide and hydroperoxide) in both Caco2 and HepG2 cell lines (p < 0.05; Table 2). ROS 
(superoxide) formation in HepG2 cells after BR incubation was positively related to apoptosis (r 
0.704, p < 0.01). 
3.2.3. Biliverdin, biliverdin dimethyl ester 
Following BV incubation in Caco2 cells a positive correlation was determined between DNA-
damaging effects and ROS formation (Table 2). In HepG2 cells BV-DME-based comet 
formation significantly correlated with apoptosis (p < 0.05; Table 2). In HepG2 cells ROS 





Table 1. Mean % tail DNA in Caco2 and HepG2 cells (± SD) after 24 hrs TP incubations, 
compared to positive and negative controls. 
Caco2 
    
Tetrapyrrole % tail DNA  
± SD 
% tail DNA pos control  
± SD 
% tail DNA neg control  
± SD 
BR 0.5 µM 
BR 5 µM 
BR 17 µM 
18.7 ± 3p 
21.3 ± 3.8p 
13.8 ± 1.9np 
 
36.5 ± 4 
 
 
21.3 ± 3 
BRDT 0.5 µM 
BRDT 5 µM 
BRDT 17 µM 
10.8 ± 2.6np 
11.7 ± 2.6p 
18.2 ± 4.1p 
 
29.1 ± 2.7 
 
7.7 ± 2.0 
 
BR-DME 0.5 µM 
BR-DME 5 µM 
BR-DME 17 µM 
8.7 ± 2.7 
11.5 ± 2.3p 
15.0 ± 6.9p 
 
21.9 ± 3.9 
 
 
9.9 ± 4.0 
 
BV 0.5 µM 
BV 5 µM 
BV 17 µM 
20.9 ± 4.3p 
20.8 ± 2.9 
18.4 ± 2.7 
 
30.1 ± 5.0 
 
 
16.5 ± 2.6 
BV-DME 0.5 µM 
BV-DME 5 µM 
BV-DME 17 µM 
15.6 ± 3.5p 
15.3 ± 3.2p 
12.9 ± 2.2p 
 
26.6 ± 2.9 
 
 
15.5 ± 2.5 
 
HepG2 
    
Tetrapyrrole % tail DNA  
± SD 
% tail DNA pos control  
± SD 
% tail DNA neg control  
± SD 
BR 0.5 µM 
BR 5 µM 
BR 17 µM 
10.8 ± 2.8 
9.2 ± 2.9 
9.7 ± 1.3 
 
18.5 ± 3.9 
 
 
9.3 ± 1.0 
BRDT 0.5 µM 
BRDT 5 µM 
BRDT 17 µM 
8.2 ± 0.8p 
8.8 ± 1.4p 
8.5 ± 1.1p 
 
13.3 ± 0.9 
 
 
7.4 ± 2.0 
 
BR-DME 0.5 µM 
BR-DME 5 µM 
BR-DME 17 µM 
8.8 ± 2.5p 
9.3 ± 1.3p 
8.7 ± 2.5 
 
13.4 ± 2.5 
 
 
6.8 ± 2.3 
 
BV 0.5 µM 
BV 5 µM 
BV 17 µM 
17.2 ± 1.4n 
15.1 ± 0.9np 
16.6 ± 1.3n 
 
16.8 ± 0.7 
 
 
12.3 ± 1.0 
BV-DME 0.5 µM 
BV-DME 5 µM 
BV-DME 17 µM 
17.0 ± 2.2np 
14.6 ± 2.0p 
17.8 ± 1.4np 
 
21.6 ± 2.1 
 
 
12.3 ± 1.6 
 
BR: unconjugated bilirubin, BRDT: bilirubin ditaurate, BV: biliverdin, BV-DME: biliverdin dimethyl 
ester, TP: tetrapyrrole. 
psignificantly different to positive control (p ≤ 0.05) 
nsignificantly different to negative control (p ≤ 0.05) 

























Figure 1 A – C. DNA-damaging effects of (A) protoporphyrin, (B) urobilin and (C) stercobilin in Caco2 
cells. 
*n: significantly different to negative control (p ≤ 0.05) 


























Figure 2 A – C. DNA-damaging effects of A) protoporphyrin, B) urobilin and C) stercobilin in HepG2 
cells. 
*n: significantly different to negative control 
*p: significantly different to positive control 




Table 2. Correlations (r) of comet tail DNA percentages (% tail DNA) and flow cytometry 
parameters in Caco2 and HepG2 cells. 
 DNA damage/comet formation (% tail DNA) 
Caco2 BR BRDT BV SB PRO 










 DNA damage/comet formation (% tail DNA) 
HepG2 BR BRDT BV-DME UB PRO 







   0.583 
p=0.036 
 
BR: unconjugated bilirubin, BRDT: bilirubin ditaurate, BR-DME: bilirubin dimethyl ester, BV: 
biliverdin, BV-DME: biliverdin dimethyl ester, UB: urobilin, SB: stercobilin, PRO: protoporphyrin.  





























Figure 3 A – C. Effects of 24 hrs PRO (A), UB (B) and SB (C) incubation in Caco2 cells, on cell cycle 
progression (annexinV-staining).  
PRO: protoporphyrin, UB: urobilin, SB: stercobilin; *n: significantly different to negative control (p ≤ 





























Figure 4 A – C. Effects of 24 hrs PRO (A), UB (B) and SB (C) incubation in HepG2 cells, on cell cycle 
progression (annexinV-staining).  
PRO: protoporphyrin, UB: urobilin, SB: stercobilin; *n: significantly different to negative control (p ≤ 




4. Discussion:  
In this study, a range of physiologically abundant TPs (BR, BRDT, BV, UB, SB, PRO) were 
investigated with non-physiological BR- and BV-DME, to test their effects on ROS 
accumulation, DNA-damage (comet formation) and apoptosis in HepG2 and Caco2 cell lines. 
Most of the investigated TPs were found to induce DNA-damage in Caco2 and HepG2 cells, 
and effects appeared to be most pronounced with intestinal TPs (SB, UB, PRO; Fig. 1A – C and 
2A - C). Cell viability data (for all tests between 86 and 99 % viability; not shown) showed no 
significant differences between the tested TP concentrations and negative controls. Therefore, it 
can be concluded that comet formation was not due to acute cytotoxic effects, but was 
predicated by mild TP-induced DNA damage. This was confirmed in both cell lines by elevated 
levels of apoptosis after BR, PRO and SB incubation (supplementary material 2; Fig. 3A – C 
and 4A – C), as well as by the lack of positive correlation between DNA-damage and necrosis 
(Table 2). These data suggest that intestinal BPs induce non-acute toxicity in malignant hepatic 
and intestinal cancer cells in vitro.  
Single- and double strand DNA breaks represent critical damage to healthy cells [30]. Whilst 
mild impairment can yet activate innate repair mechanisms, severe nucleotide breaks can trigger 
cell death including apoptosis and/or tumorigenesis [39, 40], the latter resulting from genetic 
amplification or translocation processes leading to oncogene activation [30]. In contrast, 
radiation [41] and chemotherapeutic treatment can overwhelm cellular repair systems by 
inducing the production of ROS, which attack and fragment cancer cell DNA, and can cause 
apoptosis in tumor cells [42]. Cell survival after imperfect repair of DNA-damage on the other 
hand, can lead to carcinogenesis through mutations, and the formation of many tumors has been 
associated with the inhibition of apoptosis [43, 44].  
Bile pigments (particularly BR) are known for their antioxidant activity at low to moderate 
concentrations, however, can possess pro-oxidant activity at high concentrations [6, 45]. 
Furthermore it is important to note that the ratio of BR to albumin represents an important 
determinant of ‘free’ BR [46]. This concentration influences the degree to which unbound BR 
can diffuse into cells [47] and interact with the mitochondrial membrane, where it may induce 
depolarization leading to apoptosis [19]. It is currently unknown whether also related TPs 
interact with albumin and how they interact with cells within the human organism. Clearly, 
further pharmacokinetic and bio-distribution studies are required to reveal the in vivo fate and 




In the present study, BR provoked intracellular ROS accumulation (Table 2). This result had 
been observed previously [27], and BR’s anti-cancer behavior had been discussed with 
reference to a pro-oxidant effect. Particularly with regard to BR, observed toxic or pro-oxidant 
effects in HepG2 cells seen in the present study (Table 2; online supplementary material 2), can 
probably be explained by a relatively higher “free” BR concentration in the cell culture media 
administered to HepG2 cells (10 % FBS addition), compared to the higher albumin binding 
capacity present in Caco2 cell media (20 % FBS addition). It is likely that the mildly elevated 
“free” bilirubin concentration resulted in BR absorption [47] into the mitochondrial membrane, 
leading to mitochondrial dysfunction and increased superoxide and hydrogen peroxide 
production, by interfering with mitochondrial cytochrome function [48]. Therefore, we 
hypothesize that BR, despite its known antioxidant potential, cannot neutralize increased 
production of reactive oxygen species, during mitochondrial depolarization/dysfunction.  
As initially stated, DNA-damage is frequently associated with increased ROS production. With 
relevance to ROS-induced effects, correlations between DNA-damage and ROS formation 
(superoxide) were found in PRO and BR conditions in HepG2, as well as in BV and BR 
conditions in Caco2 cells (hydroperoxide). This emphasizes the compounds’ potential role in 
causing ROS-mediated cell death in cancer cells. Elevated oxidative stress after PRO 
administration in rat hepatocytes had also been reported earlier, in which elevated superoxide 
formation had been assumed based upon an elevated superoxide dismutase (SOD) activity [49]. 
Elevated superoxide radical formation has also been detected in vitro after PRO administration 
using spin trapping techniques [50].  
With the remaining TPs (BRDT, UB, SB, BR-/BV-DME) no relationships with ROS formation 
were found in this study. These data suggest that these compounds either induced DNA-damage 
directly by interfering with DNA or associated molecules, or that radical species other than 
those measured, account for the observed DNA-damage. In some cases (PRO and BR in HepG2 
cells), ROS formation was correlated to apoptosis, which supports a role for the induction of 
oxidation by certain BPs, leading to cancer cell death via activation of apoptotic pathways.  
Information regarding the regulation of cell cycle (particularly G0/1; Fig. 3A - C and 4A - C) 
provides further important data for mechanistically explaining cytotoxic results reported in the 
comet assay. Comet formation in both cell lines, and specifically in HepG2 cells after SB, UB 
and PRO incubations (Fig. 1A – C and 2A – C) are supported by an accumulation of cells in 
G0/1 phase and an increase in apoptosis, measured using annexinV staining (Fig. 3A – C and 
4A - C). This conclusion is particularly evident for SB-induced DNA-damage, which is 




reference to these data, SB had the strongest effects on G0/1 cell cycle accumulation and 
apoptosis in both cell lines. In general, SB and PRO induced more pronounced effects 
especially in Caco2 cells, whereas UB’s effects on apoptosis were comparatively mild (Fig. 3A - 
C). 
In summary, the current results indicate that BPs such as PRO, BR and BV induce radical 
formation that is related to DNA-damage, which was associated with increased apoptosis (PRO, 
BR). Since correlations with ROS formation (superoxide and hydroperoxide) were not found in 
all test conditions, it is also possible that other radical species had been formed such as 
carbon/nitrogen-centered radicals, which were not detected by the assays utilized in this study. 
Generally speaking, DNA-damage was induced by TPs leading to elevated ROS production, 
which agrees with a possible mechanism of DNA damage proposed by Goodsell [42]. In this 
model, reactive forms of oxygen attack and differently fragment cancer cell DNA involving 
single- and double stand breaks, and lead to cell death via cell cycle arrest and subsequent 
apoptosis induction.  
In normally proliferating lymphocyte cultures, used as a model of healthy human tissue, no 
increased micronuclei- [13] and comet formation (submitted elsewhere) in the presence of 
mildly elevated circulating BR have been found recently by our work-group. These data further 




Bile pigments with structurally related TPs are reported to possess anti-mutagenic and anti-
oxidant effects in vitro, and to be of physiological importance by inhibiting oxidative stress in 
vivo and thereby preventing chronic disease [9]. However, data concerning the potential toxic 
effects of these compounds in cancer cells (beyond BR and PRO) are lacking. This study 
revealed substantial DNA-damaging effects of tetrapyrrolic compounds in human cancer cells, 
particularly for PRO, UB and SB in HepG2 and for PRO in Caco2 cell lines. From this 
evidence, a chemopreventive effect of the compounds might exist within the liver and intestine. 
Possible underlying mechanisms of DNA-damage (e. g. including ROS formation), leading to 
cell cycle arrest and subsequent apoptosis induction might be responsible for the toxicity 




Subsequent future experiments could focus on clarifying the effects of TPs also in non-
malignant cells as well as the pigments’ DNA-damaging potential in a range of various other 
cancer cell lines. Furthermore, exploring the effects of TPs also on chromosomal stability (e. g. 
prevention of micronuclei formation) could represent a valuable future scientific approach. 
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Supplementary material 2. Effects of 24 hrs BR incubation in Caco2 (A) and HepG2 (B) cell lines, on cell 
cycle progression (annexinV-staining). 
BR: unconjugated bilirubin; *n: significantly different to negative control (p < 0.05).   
 
